Zymeworks (ZYME) 10-K 2 Mar 20 2019 FY Annual report Financial data

Cover Page

Cover Page - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Feb. 27, 2020	Jun. 30, 2019
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Entity Registrant Name	ZYMEWORKS INC.
Trading Symbol	ZYME
Entity Central Index Key	0001403752
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Address, State or Province	BC
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Shares
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding		45,518,869
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	Yes
Entity Public Float			$ 851.7
Entity File Number	001-38068
Entity Incorporation, State or Country Code	CA
Entity Tax Identification Number	47-2569713
Entity Address, Address Line One	Suite 540—1385 West 8th Avenue
Entity Address, City or Town	Vancouver
Entity Address, Postal Zip Code	V6H 3V9
Local Phone Number	678-1388
City Area Code	604
Document Annual Report	true
Document Transition Report	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 128,451	$ 42,205
Short-term investments (note 5)	170,453	157,959
Accounts receivable	2,185	358
Prepaid expenses and other current assets	10,741	3,847
Total current assets	311,830	204,369
Deferred financing fees	650	265
Long-term prepaid assets	2,306	1,135
Deferred tax asset (note 15)	1,218	198
Property and equipment, net (note 7)	11,100	6,484
Operating lease right-of-use assets (note 16)	5,400
Intangible assets, net (note 8)	6,057	1,614
Acquired in-process research and development (note 6)	17,628	18,396
Goodwill (note 6)	12,016	12,016
Total assets	368,205	244,477
Current liabilities:
Accounts payable and accrued liabilities (note 9)	35,691	13,403
Fair value of liability classified options (note 17)	45,569	12,603
Current portion of operating lease liability (note 16)	1,282
Current portion of deferred revenue (note 13)		3,530
Other current liabilities	10	450
Total current liabilities	82,552	29,986
Long-term portion of operating lease liability (note 16)	5,599
Long-term portion of deferred revenue (note 13)	32,941	32,941
Other long-term liabilities (note 9)	1,024	946
Deferred tax liability (note 15)	408	114
Total liabilities	122,524	63,987
Shareholders' equity:
Common shares, no par value; unlimited authorized shares at December 31, 2019 and 2018; 39,564,529 and 31,977,668 shares issued and outstanding at December 31, 2019 and 2018, respectively (note 11b)	450,210	320,074
Additional paid-in capital	92,839	12,347
Accumulated other comprehensive loss	(6,659)	(6,659)
Accumulated deficit	(290,709)	(145,272)
Total shareholders' equity	245,681	180,490
Total liabilities and shareholders' equity	$ 368,205	$ 244,477

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Common shares, no par value	$ 0	$ 0
Common shares, issued	39,564,529	31,977,668
Common shares, outstanding	39,564,529	31,977,668
Common Stock, Shares Authorized, Unlimited [Fixed List]	Unlimited	Unlimited

Consolidated Statements of Loss

Consolidated Statements of Loss and Comprehensive Loss - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Revenue
Research and development collaborations (note 13)		$ 29,544	$ 53,019	$ 51,762
Operating expenses
Research and development, net of government grants and credits		115,900	56,926	41,144
General and administrative		64,177	29,457	18,550
Impairment on acquired IPR&D (note 6)		768		1,536
Total operating expenses		180,845	86,383	61,230
Loss from operations		(151,301)	(33,364)	(9,468)
Other income (expense):
Interest and other income		6,022	2,638	743
Other expense, net (note 14)		(740)	(3,659)	(1,237)
Total other income (expense), net		5,282	(1,021)	(494)
Loss before income taxes		(146,019)	(34,385)	(9,962)
Income tax recovery (expense), net (note 15)		582	(2,171)	(444)
Net loss and comprehensive loss		$ (145,437)	$ (36,556)	$ (10,406)
Net loss per common share (note 4):
Basic		$ (3.83)	$ (1.26)	$ (0.51)
Diluted		$ (3.83)	$ (1.26)	$ (0.64)
Weighted-average common shares outstanding (note 4):
Basic	[1]	38,022,014	29,089,896	21,249,414
Diluted		38,022,014	29,089,896	21,321,209
[1]	Weighted average number of common shares used in the basic earnings per share calculation for the three and nine months ended December 31, 2019 includes the pre-funded warrants issued in connection with the Company’s June 2019 offering as the warrants are exercisable at any time and for nominal cash consideration.

Consolidated Statements of Chan

Consolidated Statements of Changes in Redeemable Convertible Preferred Shares and Shareholders' Equity - USD ($) $ in Thousands	Total	Redeemable Convertible Class A Preferred Shares [Member]	Common Shares [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Additional Paid-in Capital [Member]
Beginning balance at Dec. 31, 2016	$ 9,002		$ 106,595	$ (97,790)	$ (6,659)	$ 6,856
Beginning balance, shares at Dec. 31, 2016			13,126,248
Temporary equity balance at Dec. 31, 2016		$ 58,860
Temporary equity balance, shares at Dec. 31, 2016		5,260,404
Issuance of common shares on exercise of warrants	1,563		$ 1,563
Issuance of common shares on exercise of warrants, shares			117,320
Issuance of common shares on exercise of options	1,265		$ 1,777			(512)
Issuance of common shares on exercise of options, shares			207,777
Fair value adjustments upon reclassification of options to liabilities	(2,879)					(2,879)
Stock-based compensation	4,827					4,827
Beneficial conversion feature recognized on the conversion of redeemable convertible class A preferred shares (note 11c)				(520)		520
Conversion of redeemable convertible class A preferred shares to common shares in connection with initial public offering (note 11c)	58,860		$ 58,860
Conversion of redeemable convertible class A preferred shares to common shares in connection with initial public offering (note 11c), shares			7,098,194
Conversion of redeemable convertible class A preferred shares to common shares in connection with initial public offering		$ (58,860)
Conversion of redeemable convertible class A preferred shares to common shares in connection with initial public offering, shares		(5,260,404)
Issuance of common shares in connection with initial public offering, net of offering costs	54,196		$ 54,196
Issuance of common shares in connection with initial public offering, net of offering costs, shares			4,894,467
Net loss	(10,406)			(10,406)
Ending balance at Dec. 31, 2017	116,428		$ 222,991	(108,716)	(6,659)	8,812
Ending balance, shares at Dec. 31, 2017			25,444,006
Temporary equity balance at Dec. 31, 2017		$ 0
Temporary equity balance, shares at Dec. 31, 2017		0
Issuance of common shares on exercise of warrants	4,913		$ 4,913
Issuance of common shares on exercise of warrants, shares			206,361
Issuance of common shares through employee stock purchase plan	252		$ 252
Issuance of common shares through employee stock purchase plan, shares			22,489
Issuance of common shares on exercise of options	825		$ 1,166			(341)
Issuance of common shares on exercise of options, shares			94,812
Stock-based compensation	3,876					3,876
Issuance of common shares in connection with initial public offering, net of offering costs	90,752		$ 90,752
Issuance of common shares in connection with initial public offering, net of offering costs, shares			6,210,000
Net loss	(36,556)			(36,556)
Ending balance at Dec. 31, 2018	$ 180,490		$ 320,074	(145,272)	(6,659)	12,347
Ending balance, shares at Dec. 31, 2018	31,977,668		31,977,668
Issuance of common shares through employee stock purchase plan	$ 763		$ 763
Issuance of common shares through employee stock purchase plan, shares			43,308
Issuance of common shares on exercise of options	9,303		$ 11,432			(2,129)
Issuance of common shares on exercise of options, shares			529,661
Fair value adjustments upon reclassification of options to liabilities	(119)					(119)
Stock-based compensation	12,676					12,676
Issuance of common shares in connection with initial public offering, net of offering costs	188,005		$ 117,941			70,064
Issuance of common shares in connection with initial public offering, net of offering costs, shares			7,013,892
Net loss	(145,437)			(145,437)
Ending balance at Dec. 31, 2019	$ 245,681		$ 450,210	$ (290,709)	$ (6,659)	$ 92,839
Ending balance, shares at Dec. 31, 2019	39,564,529		39,564,529

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net loss	$ (145,437)	$ (36,556)	$ (10,406)
Items not involving cash:
Depreciation of property and equipment	2,312	1,880	1,681
Amortization of intangible assets	3,113	1,750	1,058
Impairment on acquired IPR&D	768		1,536
Stock-based compensation (note 11e)	48,996	13,441	3,429
Amortization of operating lease right-of-use assets	1,906
Deferred income tax (recovery) expense	(726)	(17)	15
Change in fair value of contingent consideration (note 18)	271	237	470
Change in fair value of warrant liabilities (note 10)		3,565	(2,450)
Accretion on long-term debt			248
Loss on debt extinguishment			3,114
Unrealized foreign exchange loss/(gain)	504	(48)	(254)
Changes in non-cash operating working capital:
Accounts receivable	(1,828)	(119)	2,409
Prepaid expenses and other current assets	(8,680)	(251)	(202)
Accounts payable and accrued liabilities	21,572	3,684	(358)
Operating lease liabilities	(795)
Deferred revenue	(3,530)	36,471
Income taxes payable	(299)	140	(71)
Net cash (used in) provided by operating activities	(81,853)	24,177	219
Cash flows from financing activities:
Proceeds from initial public offering, net of issuance costs (note 11a)			55,791
Proceeds from subsequent public offerings, net of issuance costs (note 11a)	188,231	90,752
Issuance of common shares on exercise of options (note 11e)	5,498	682	965
Issuance of common shares on exercise of warrants (note 10)			1,018
Issuance of common shares through employee stock purchase plan (note 11h)	598	233
Repayment of debt (note 10)			(7,814)
Deferred financing fees	(650)	(225)
Finance lease payments	(16)	(11)	(9)
Net cash provided by financing activities	193,661	91,431	49,951
Cash flows from investing activities:
Purchase of short-term investments	(11,714)	(105,626)	(27,767)
Acquisition of property and equipment	(6,322)	(803)	(2,015)
Acquisition of intangible assets	(7,556)	(2,617)	(1,106)
Net cash used in investing activities	(25,592)	(109,046)	(30,888)
Effect of exchange rate changes on cash and cash equivalents	30	(303)	227
Net change in cash and cash equivalents	86,246	6,259	19,509
Cash and cash equivalents, beginning of year	42,205	35,946	16,437
Cash and cash equivalents, end of year	128,451	42,205	35,946
Supplemental disclosure of non-cash investing and finance items:
Leased assets obtained in exchange for operating lease liabilities	7,026
Acquisition of property and equipment in accounts payable and accrued liabilities	$ 607	382	$ 123
Cashless exercise of warrants (note 10)		$ 4,913

Nature of Operations

Nature of Operations	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	1. Nature of Operations Zymeworks Inc. Since its inception, the Company has devoted substantially all of its resources to research and development activities, including developing its therapeutic platforms, identifying and developing potential product candidates by undertaking preclinical studies and clinical trials. The Company supports these activities through general and administrative support, as well as by raising capital, conducting business planning and protecting its intellectual property.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). The consolidated financial statements include the accounts of Zymeworks Inc. and its wholly owned subsidiar y on All amounts expressed in the consolidated financial statements of the Company and the accompanying notes thereto are expressed in thousands of U.S. dollars, except for share and per share data and where otherwise indicated. References to “$” are to U.S. dollars and references to “C$” are to Canadian dollars. Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. Foreign Currency The functional currency of the Company is the U.S. dollar. Transactions denominated in foreign currencies are translated at the approximate exchange rate prevailing on the date of the transaction. At period end, monetary assets and liabilities denominated in foreign currencies are translated into U.S. dollars using exchange rates in effect at the balance sheet date. Resulting foreign exchange gains and losses are reflected in the Consolidated Statements of Loss and Comprehensive Loss. Use of Estimates The preparation of the financial statements in accordance with U.S. GAAP requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, some of which are those related to revenue recognition including estimated timing of completion of performance obligations required to meet revenue recognition criteria, accrual of expenses including clinical and preclinical study expense accruals, stock-based compensation, valuation allowance for deferred taxes, benefits under the Scientific Research and Experimental Development (“SR&ED”) Program, and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates. Revenue Recognition Effective January 1, 2018, the Company adopted on a modified retrospective basis Accounting Standards Codification Topic 606, Revenue from Contracts with Customers The Company applied ASC 606 to all arrangements to date. For collaborative arrangements that fall within the scope of ASC 808, Collaborative Arrangements (“ASC 808”), the Company applies the revenue recognition model under ASC 606 to part or all of the arrangement, when deemed appropriate. In accordance with ASC 606, the Company recognizes revenue when the Company’s customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised deliverables in the contract; (ii) determination of whether the promised deliverables are performance obligations including whether they are distinct; (iii) measurement of the transaction price, including uncertainties related to variable consideration; (iv) allocation of the transaction price to the performance obligations based on the stand-alone selling prices; and (v) recognition of revenue when or as the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration that it is entitled to in exchange for the goods and services transferred to the customer. At contract inception, the Company assesses the goods or services promised within each contract that falls under the scope of Topic 606, to identify distinct performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. The Company has entered into a number of collaboration and licensing agreements. Promised deliverables within these agreements may include: (i) grants of licenses, or options to obtain licenses, to the Company’s intellectual property, (ii) research and development services, (iii) drug product manufacturing, and (iv) participation on joint research and/or development committees. The terms of these agreements typically include one or more of the following types of payments to the Company: • non-refundable, • research, development and regulatory milestone payments; • research support payments; and • royalties and commercial milestone payments. If the expectation at contract inception is such that the period between payment by the licensee and the completion of related performance obligations will be one year or less, the Company assumes that the contract does not have a significant financing component. When applying the revenue recognition criteria of ASC 606 to license and collaboration agreements, the Company may be required to apply significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining when performance obligations have been met, assessing the recognition and future reversal of variable consideration, and determining and applying appropriate methods of measuring progress for performance obligations satisfied over time. These judgments are discussed in more detail in the following paragraphs for each type of payment received by the Company under the terms of the license and collaborations agreements. Non-refundable, If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, non-refundable, Research, development and regulatory milestone payments At the inception of each arrangement that includes research, development or regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. When it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates catch-up Research and development milestones in the Company’s collaboration agreements may include some, but not necessarily all, of the following types of events: • completion of preclinical research and development work leading to selection of product candidates; • initiation of Phase 1, Phase 2 and Phase 3 clinical trials; and • achievement of certain other technical, scientific or development criteria. Regulatory milestone payments may include the following types of events: • filing of regulatory applications for marketing approval in the United States, Europe or Japan, including Investigational New Drug (“IND”) applications and Biologics License Application (“BLA”); and • marketing approval in major markets, such as the United States, Europe or Japan. Research support and other payments Payments by the licensees in exchange for research activities performed by the Company on behalf of the licensee are recognized as revenue upon performance of such activities at rates consistent with prevailing market rates. Payments for research supplies provided are recognized as revenue upon delivery of the supplies. Royalties and commercial milestone payments For arrangements that include sales-based royalties, including commercial milestone payments based on pre-specified Contract Assets and Liabilities Contract assets are mainly comprised of trade receivables net of allowance for doubtful debts, which includes amounts billed and currently due from customers. Contract liabilities are mainly comprised of deferred revenues. Amounts received prior to satisfying all revenue recognition criteria are recorded as deferred revenue in the Company’s consolidated financial statements. Amounts not expected to be recognized as revenue within the next twelve months of the consolidated balance sheet date are classified as long-term deferred revenue. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of 90 days or less at the date of acquisition to be cash equivalents. Cash and cash equivalents consist primarily of money market funds and are recorded at cost, which approximates fair value. Short-Term Investments The Company’s short-term investments consist of guaranteed investment certificates and term deposits with original maturities exceeding three months and less than one year. The investments are recorded at cost plus accrued interest, which approximates their fair value. Accounts Receivable a nd Allowance for Doubtful Accoun ts Accounts receivable are recorded at invoiced amounts, net of any allowance for doubtful accounts. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in existing accounts receivable. The Company evaluates the collectability of accounts receivable on a regular basis based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. There is no allowance for doubtful accounts recorded as at December 31, 2019 and 2018. Deferred Financing Fees Deferred financing fees amount s upon closing of such tra nsaction. Segment Information The Company operates and manages its business in one segment, which is the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. Property and Equipment Property and equipment are recorded at cost net of accumulated depreciation. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in earnings. Repairs and maintenance costs are expensed as incurred. The Company records depreciation using the straight-line method over the estimated useful lives of the property and equipment as follows: Asset Class Rate Computer hardware 3 Office equipment 3 Furniture and fixtures 5 Laboratory equipment 7 Leasehold improvements Shorter of the initial lease term or useful life Property and equipment acquired or disposed of during the year are depreciated proportionately for the period they are in use. Patents and Intellectual Property Costs Costs incurred to acquire patents and to prosecute and maintain intellectual property rights are expensed as incurred to general and administrative expense due to the uncertainty surrounding the drug development process and the uncertainty of future benefits. Patents and intellectual property acquired from third parties are capitalized and amortized over the remaining life of the patent, if related to fo r the underlying technol ogy Impairment of Long-Lived Assets The Company assesses the recoverability of its long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or group of assets. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset or asset group. Assets classified as held for sale are reported at the lower of the carrying amount or fair value, less costs to sell. As of December 31, 2019 and 2018, the Company determined that there were no impairments of long-lived assets and no assets held-for-sale. Government Grants and Credits Government grants are recognized where there is reasonable assurance that the grant will be received and all associated conditions will be complied with. Reimbursements of eligible research and development expenditures pursuant to government assistance programs are recorded as reductions of research and development costs when the related costs have been incurred and there is reasonable assurance regarding collection of the claim. Grant claims not settled by the balance sheet date are recorded as receivables, provided their receipt is reasonably assured. The determination of the amount of the claim, and hence the receivable amount, requires management to make calculations based on its interpretation of eligible expenditures in accordance with the terms of the programs. The reimbursement claims submitted by the Company are subject to review by the relevant government agencies. The Company has used its best judgment and understanding of the related program agreements in determining the receivable amount. The Company participates in SR&ED and Research Tax Credit Programs, two federal tax incentive programs that encourage Canadian and U.S. businesses to conduct research and development in Canada and in U.S. respectively. The benefits of investment tax credits for scientific research and development expenditures are recognized in the year the qualifying expenditure is made provided there is reasonable assurance of recoverability. These investment tax credits are recorded as reductions to research and development expenditures. Research and Development Costs Research and development costs are expensed as incurred and include costs that the Company incurs for its own and for the Company’s strategic partners’ research and development activities. These costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations on the Company’s behalf, investigative sites and consultants that conduct the Company’s clinical trials, the cost of acquiring and manufacturing clinical trial materials and other allocated expenses, stock-based Clinical Trial Expense Accruals Clinical trial expenses represent a significant component of research and development expenses and the Company outsources a significant portion of these activities to third party contract research organizations. Third-party clinical trial expenses include investigator fees, site costs, clinical research organization costs and other trial-related vendor costs. As part of preparing the Income Taxes The Company accounts for income taxes using an asset and liability approach. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The measurement of deferred tax assets is reduced, if necessary, by the extent of a valuation allowance. The recognition of uncertain tax positions is evaluated based on whether it is considered more likely than not that the position taken, or expected to be taken, on a tax return will be sustained upon examination through litigation or appeal. For those positions that meet the recognition criteria, they are measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement. Interest and tax penalties are expensed as incurred. Stock-Based Compensation The Company recognizes stock-based compensation expense on equity and liability classified stock-based awards granted to employees, directors, and certain consultants. The Company measures the cost of such awards based on the fair value of the award, net of estimated forfeitures, and recognizes stock-based compensation expense in the consolidated statements of loss and comprehensive loss on a straight-line basis over the requisite service period. The requisite service period generally equals the vesting period of the awards. The fair values of the awards are estimated using the Black-Scholes option pricing model which uses various inputs including estimated fair value of the Company’s underlying common share at the grant date, expected term, estimated volatility, risk-free interest rate and expected dividend yields of the Company’s common shares. The Company applies an estimated forfeiture rate derived from historical employee termination behavior. If the actual number of forfeitures differs from those estimated by management, adjustments to compensation expense may be required in future periods. Equity classified awards are measured using their grant date fair value. Liability classified awards are initially measured using their grant date fair value and are subsequently remeasured at fair value at each balance sheet date until exercised or cancelled, with changes in fair value recognized as compensation cost (ASC 718 awards) or additional paid-in Awards accounted for under Accounting Standards Codification (“ASC”) 718 “Compensation—Stock Options” (“ASC 718”), with an exercise price which is not denominated in: (a) the currency of a market in which a substantial portion of the Company’s equity securities trades, (b) the currency in which the individual’s pay is denominated, or (c) the Company’s functional currency, are required to be classified as liabilities. For awards accounted for under ASC 815 “Derivatives and Hedging” (“ASC 815”), any warrant or option that provides for an exercise price which is not denominated in the Company’s functional currency is required to be classified as a liability. Certain option awards which were classified as equity on grant dates were subsequently reclassified to liability: • Upon the change of the compensation currency for certain executives from Canadian dollars to U.S. dollars effective January 1, 2017 held by such executives which were previously classified as equity awards per ASC 718 on January 1, 2017 have been reclassified as liability awards of which $2,879 was reclassified from additional paid-in capital and the remaining $4,492 was recorded to the statement of loss on January 1, 2017 as under ASC 718 statement of loss • Upon the change of the compensation currency for a certain executive from Canadian dollars to U.S. dollars effective January 1, paid-in The Company has an employee stock purchase plan which is considered compensatory. Accordingly, the Company recognizes compensation expense on these awards based on their estimated grant date fair value using the Black-Scholes option pricing model. The Company recognizes compensation expense in the consolidated statements of loss and comprehensive loss on a straight-line basis over the requisite service period. Business Combinations and Goodwill Business combinations are accounted for using the acquisition method. The fair value of total purchase consideration is allocated to the fair values of identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount being classified as goodwill. All assets, liabilities and contingent liabilities acquired or assumed in a business combination are recorded at their fair values at the date of acquisition. If the Company’s interest in the fair value of the acquiree’s net identifiable assets exceeds the cost of the acquisition, the excess is recognized in earnings or loss immediately. Transaction costs that are incurred in connection with a business combination, other than costs associated with the issuance of debt or equity securities, are expensed as incurred. Goodwill is evaluated for impairment on an annual basis or more frequently if an indicator of impairment is present (note 6). As part of the impairment evaluation, the Company may elect to perform an assessment of qualitative factors. If this qualitative assessment indicates that it is more likely than not that the fair value of the reporting unit that includes the goodwill is less than its carrying value, then a quantitative impairment test would be prepared to compare the fair value to the carrying value and record an impairment charge if the carrying value exceeds the fair value. Acquired In-Process Acquired IPR&D represents the fair value assigned to research and development assets that have not reached technological feasibility. IPR&D is classified as an indefinite-lived intangible asset and is not amortized. IPR&D becomes definite-lived upon the completion or abandonment of the associated research and development efforts. All research and development costs incurred subsequent to the acquisition of IPR&D are expensed as incurred. Indefinite-lived intangible assets are evaluated for impairment on an annual basis or more frequently if an indicator of impairment is present. Definite-lived intangible assets include computer software and a research license and are amortized on a basis which reflects the pattern in which the economic benefits are consumed. Amortization begins when the assets are put into use. If there is a event indicating that the carrying value of a definte-lived intangible asset may be impaired, then the Company will perform an impairment test. When an impairment test is performed, if the carrying value exceeds the recoverable value, based on the sum of undiscounted future cash flows, then such asset is written down to its fair value. Net loss per share Basic net loss per share attributable to common shareholders is computed by dividing the net loss attributable to common shareholders by the weighted average number of common shares outstanding for the year. Diluted net loss per share attributable to common shareholders is computed by adjusting net loss attributable to common shareholders to reallocate undistributed earnings based on the potential impact of dilutive securities, including outstanding redeemable convertible Class A preferred shares, stock options and warrants. Diluted net loss per share attributable to common shareholders is computed by dividing the diluted net loss attributable to common shareholders by the weighted-average number of common shares outstanding for the year, including potential dilutive common shares assuming the dilutive effect of outstanding instruments. The if-converted

Recent Accounting Pronouncement

Recent Accounting Pronouncements	12 Months Ended
	Dec. 31, 2019
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	3. Recent Accounting Pronouncements Adoption of Topic 842 (Leases) On January 1, 2019 the Company adopted Topic 842 using the modified retrospective approach with a cumulative-effect adjustment to accumulated deficit as of January 1, 2019 in accordance with ASU No. 2018-11, Leases (Topic 842)—Targeted Improvements year Dec ember 31 Leases non-lease The impact of the adoption of Topic 842 on the accompanying c b s December 31, Adjustments January 1, Operating lease right-of-use (1) $ — $ 3,222 $ 3,222 Total lease inducements (2) 333 (333 ) — Total operating lease liabilities (3) — 3,561 3,561 (1) Right-of-use Right-of-use (2) Included in current and long-term other liabilities (note 9) (3) Includes current and non-current The adjustments due to the adoption of Topic 842 primarily related to the recognition of operating lease right-of-use The Company evaluated its facility leases and determined that, effective upon the adoption of Topic 842, they were all operating leases. The Company performed an evaluation of its other contracts with customers and suppliers in accordance with Topic 842 and determined that, except for the facility and equipment leases described above, none of its contracts contain a lease. The impact of the adoption of Topic 842 on the consolidated statements of loss and comprehensive loss for the year ended December 31, 2019 was as follows: As reported Effect of Balances Operating expenses for the year ended December 31, 2019 $ 180,845 $ 311 $ 180,534 See note 16 in these consolidated financial statements for additional disclosures. Adoption of other pronouncements In June 2018, the FASB issued ASU 2018–07, Compensation a significant Recent accounting pronouncements not yet adopted In August 2018, the FASB issued ASU 2018–13, Fair Value Measurement (Topic 820): Disclosure Framework In August 2018, the FASB issued ASU 2018–15, Intangibles Other – Internal Use Software (Subtopic 350–40). This ASU addresses customer’s accounting for implementation costs incurred in a cloud computing arrangement that is a service contract and also adds certain disclosure requirements related to implementation costs incurred for internal-use software and cloud computing arrangements. The amendment aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This ASU is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted . The amendments in this ASU can be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. The Company is evaluating the effect of adopting this new accounting guidance but does not expect adoption will have a material impact on the Company’s consolidated financial statements. The Company has reviewed other recent accounting pronouncements and concluded that they are either not applicable to the business, or that no material impact is expected on the consolidated financial statements as a result of future adoption.

Net Loss per Share

Net Loss per Share	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Net Loss per Share	4. Net Loss per Share Net loss per share for the years ended December 31, 2019, 2018 and 2017 was as follows: Year Ended December 31, 2019 2018 2017 Numerator Net loss attributable to common shareholders: $ (145,437 ) $ (36,556 ) $ (10,406 ) Deemed dividend due to beneficial conversion feature — — (520 ) Basic $ (145,437 ) $ (36,556 ) $ (10,926 ) Adjustment for change in fair value of ASC 815 liability classified stock options and warrant — — (2,757 ) Diluted $ (145,437 ) $ (36,556 ) $ (13,683 ) Denominator: Weighted-average common shares outstanding: Basic (*) 38,022,014 29,089,896 21,249,414 Adjustment for dilutive effect of liability classified stock options and warrants — — 71,795 Diluted 38,022,014 29,089,896 21,321,209 Net loss per common share – basic $ (3.83 ) $ (1.26 ) $ (0.51 ) Net loss per common share – diluted $ (3.83 ) $ (1.26 ) $ (0.64 ) (*): Weighted average number of common shares used in the basic earnings per share calculation for the year ended December 31, 2019 includes the pre-funded

Short-term Investments

Short-term Investments	12 Months Ended
	Dec. 31, 2019
Investments, All Other Investments [Abstract]
Short-Term Investments	5 Short-term Investments Short-term investments consist of guaranteed investment certificates (“GICs”) and term deposits held at financial institutions purchased in accordance with the Company’s treasury policy. These GICs and term deposits bear interest at 2%-3% per annum and have maturities of up to months.

IPR&D and Goodwill

IPR&D and Goodwill	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
IPR&D and Goodwill	6. IPR&D and Goodwill Acquired IPR&D In-process The following table summarizes the carrying value of IPR&D, net of impairment: Acquired IPR&D Accumulated Net Balance at December 31, 2016 $ 20,700 $ (768 ) $ 19,932 Change during the period — (1,536 ) (1,536 ) Balance at December 31, 2017 $ 20,700 $ (2,304 ) $ 18,396 Change during the period — — — Balance at December 31, 2018 $ 20,700 $ (2,304 ) $ 18,396 Change during the period — (768 ) (768 ) Balance at December 31, 2019 $ 20,700 $ (3,072 ) $ 17,628 For the year ended December 31, 2019, the Company recorded an impairment charge of $768 related to the fair value of IPR&D recognized in relation to collaboration efforts with VAR2 Pharmaceuticals ApS (“VAR2”) as the co-development Company also recorded a For the year ended December 31, 2017, the Company recorded an impairment charge of $1,536 related to the fair value of IPR&D recognized in relation to the Research Collaboration Agreement with OBT (“OBT Technology Swap Agreement”) as the Company chose not to advance the associated research and development projects within the research term which expired on February 11, 2017. Goodwill The Company performed its annual impairment test of goodwill as of December 31, 2019. As part of the evaluation of the recoverability of goodwill, the Company identified only one reporting unit to which the total carrying amount of goodwill has been assigned. As at December 31, 2019, the Company performed a qualitative assessment for its annual impairment test of goodwill after concluding that it was not more likely than not that the fair value of the reporting unit was less than its carrying value. Consequently, the quantitative impairment test was not required .

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment	7 Property and equipment consist of the following: December 31, 2019 2018 Computer hardware $ 2,438 $ 1,439 Furniture and fixtures 1,248 747 Office equipment 729 535 Laboratory equipment 6,628 5,270 Leasehold improvements 6,374 3,377 Construction in progress 915 221 Property and equipment $ 18,332 $ 11,589 Less accumulated depreciation (7,232 ) (5,105 ) Property and equipment, net $ 11,100 $ 6,484 During the year ended December 31, 2019, the Company entered into a new capital lease for office equipment of $12 (2018 – $10). Total assets under capital lease were $84 and $72 at December 31, 2019 and 2018, respectively; accumulated depreciation for these assets w as we Depreciation expense on property and equipment for the years ended December 31, 2019, 2018 and 2017 was $2,312, $1,880 and $1,681, respectively.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	8 Intangible assets consist of the following: December 31, 2019 2018 Computer software and research $ 12,985 $ 5,429 Less accumulated amortization (6,928 ) (3,815 ) Intangible assets, net $ 6,057 $ 1,614 Amortization expense on intangible assets for the years ended December 31, 2019, 2018 and 2017 was $3,113, $1,750 and $1,058, respectively.

Liabilities

Liabilities	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Liabilities	9 Accounts payable and accrued liabilities consist of the following: December 31, 2019 2018 Trade payables $ 5,349 $ 2,599 Accrued research expenses 24,262 6,633 Employee compensation and vacation accruals 5,009 2,926 Accrued legal and professional fees 231 556 Other 840 689 Total $ 35,691 $ 13,403 Other long term liabilities consisted of the following: December 31, 2019 2018 Liability for contingent consideration (note 18 $ 978 $ 707 Lease inducements — 197 Finance lease liability (note 1 6 46 42 Total $ 1,024 $ 946

Payment of long-term debt and e

Payment of long-term debt and exercise of liability classified warrants	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Payment of long-term debt and exercise of liability classified warrants	10. Payment of long-term debt and exercise of liability classified warrants Description of transaction: On June 2, 2016, the Company entered into a Credit Agreement (the “Perceptive Debt”) with Perceptive Credit Opportunities Fund L.P. and PCOF Phoenix II Fund L.P. (collectively, “Perceptive”). The total credit facility was for $15.0 million consisting of Tranche A and Tranche B term loans for $7.5 million each. The Tranche A term loan was made available to the Company on June 2, 2016, with total net proceeds received of $6,953, after deducting commissions, legal and other administrative costs. Under the Credit Agreement, the Company had the option to settle the loan earlier, subject to certain early payment premiums. P five years we c 1.349367-for-1 basis Early Repayment of the Perceptive Debt and exercise of warrants: On June 6, 2017 (the “Repayment Date”), the Company exercised its option to repay the total outstanding debt ahead of the maturity date, pursuant to the terms of the Credit Agreement. On the Repayment Date, the Company paid $7,814 which consisted of the $7,500 outstanding principal balance, a $300 early repayment premium as well as $14 in legal fees. At the time of repayment, all liabilities and obligations of the Company and Perceptive terminated automatically. The repayment did not affect Perceptive’s rights, in connection with the Perceptive From January , to June , , the Company recorded $ in interest expense, $ in accretion expense and $ in amortization of debt issue costs. Year ended December 31, Long term debt at January 1, 2017 $ 4,810 Less: unamortized debt issue costs at January 1, 2017 (393 ) Long term debt at January 1, 2017, net of deferred charges $ 4,417 Accretion during the period up to the Repayment Date 248 Amortization of debt issue costs during the period up to the Repayment Date 35 Carrying value of long term debt on the Repayment Date, net of deferred charges $ 4,700 Repayment, including repayment premium and expenses (7,814 ) Loss on debt extinguishment $ (3,114 ) On May 10, 2018, Perceptive exercised a portion of its warrants to purchase 178,076 common shares of the Company on a cashless basis, resulting in a net issuance of 79,481 common shares to Perceptive. On June 4, 2018, Perceptive exercised the remaining warrants to purchase 220,000 common shares of the Company on a cashless basis, resulting in a net issuance of 126,880 common shares to Perceptive. The fair value of the Perceptive warrants increased b y

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2019
Stockholders' Equity Note [Abstract]
Shareholders' Equity	11. Shareholders’ Equity a. Equity Offerings Initial Public Offering The Company closed its initial public offering (“IPO”) on May 3, 2017, pursuant to which the Company sold 4,894,467 common shares including the sale of 394,467 common shares to the underwriters upon their partial exercise of their over-allotment option to purchase additional shares on May 31, 2017. The public offering price of the shares sold in the IPO was $13.00 per share. The Company received net proceeds of approximately $54.2 million, after underwriting discounts, commissions and offering expenses of $9.4 million c) 2018 Public Offering On June 11, 2018, the Company closed an offering pursuant to which the Company sold common shares including the sale of common shares to the underwriters upon their full exercise of their over-allotment option at an offering price of $15.75 per share . The Company received net proceeds of approximately $ million, after underwriting discounts, commissions and offering expenses of $7.1 million 2019 Public Offering On June 24, 2019, the Company closed an offering pursuant to which the Company sold 7,013,892 common shares including the sale of 1,458,336 common shares to the underwriters upon their full exercise of their over-allotment option at an offering price of $18.00 per common share and 4,166,690 Pre-Funded (note 11d) in lieu of common shares at $17.9999 per Pre-Funded Warrant . Net proceeds were approximately $188.0 million, after underwriting discounts, commissions and offering expenses of $13.2 million b. Authorized On May , , the Company’s new Articles of Incorporation were issued under which the Company has an unlimited number of voting Common Shares and Preferred Shares without par value. Under the Company’s former Articles of Incorporation dated December , , the Company had authorized Redeemable Convertible Class A Preferred Shares. c Preferred Shares and Redeemeable Convertible Class A Preferred Shares As of December 31, 2019 and 2018, no preferred shares were issued or outstanding, respectively. The rights and preferences of the unissued Preferred Shares are as follows: Holders of Preferred Shares will be entitled to preference with respect to payment of dividends over the Common Shares and any other shares ranking junior to the Preferred Shares. In the event of the liquidation, dissolution or winding-up The Preferred Shares may also be given such other preferences over the Common Shares and any other shares ranking junior to the Preferred Shares as may be fixed by directors’ resolution as to the respective series authorized to be issued. Prior to the IPO, the Company issued Redeemable Convertible Class A Preferred Shares (“Class A Preferred Shares”). The Company assessed the issued Class A Preferred Shares for any beneficial conversion features or embedded derivatives, including the conversion option, that would require bifurcation from the applicable series of preferred shares and receive separate accounting treatment. On the date of the issuance of preferred shares, the fair value of the common shares into which the Class A Preferred Shares were convertible was less than the effective conversion price of such shares and, as such, there was no intrinsic value of the conversion option on the commitment date. There was a contingent beneficial conversion feature that would have become applicable if an initial public offering was completed at an issue price in excess of the conversion price within one year of the date the preferred shares were issued. Prior to the IPO, the Company classified its Class A Preferred Shares outside of permanent equity as the redemption of such shares was not solely under the control of the Company. Immediately prior to the consummation of the IPO, all outstanding Class A Preferred Shares were converted into 7,098,194 common shares on a 1-for-1.349367 Preferred Shares As a result of conversion the Company issued 7,098,194 common shares in exchange for 5,260,404 Class A Preferred Shares. The paid-in d Pre-Funded On June 24, 2019, the Company completed a public offe r a nd P F W P F W the right Pre-Funded Pre-Funded Pre-Funded W As the Pre-Funded Warrants meet the condition for equity classification, proceeds from issuance of the Pre-Funded Warrants, net of any transaction costs, are recorded in additional paid-in capital. Upon exercise of the Pre-Funded Warrants, the historical costs recorded in additional paid-in capital along with the Exercise Price collected from holders will be recorded in common shares. e Stock-Based Compensation Original Stock Option Plan: On July 14, 2006, the shareholders approved an employee stock option plan (the “Original Plan”). The Original Plan provides for the granting of options to directors, officers, employees and consultants. Options to purchase common shares may be granted at an exercise price of each option equal to the last private issuance of common shares immediately preceding the date of the grant. The total number of options outstanding is not to exceed 20% of the issued common shares of the Company. Options granted under the Original Plan are exercisable at various dates over their ten-year Options issued to employees under the Original Plan vest over 4 years. Options issued to directors under the Original Plan vest over 3 years, and options issued to consultants and members of the Scientific Advisory Board under the Original Plan vest immediately upon issuance. The exercise prices of the Company’s stock options under the Original Plan foreign exchange New Stock Option Plan: On April 10, 2017, the Company’s shareholders approved a new stock option plan, which became effective immediately prior to the consummation of the IPO. This plan allowed for the grant of options to directors, officers, employees and consultants in U.S. or Canadian dollars, and also permitted the Company to grant incentive stock options (“ISOs”), within the meaning of Section 422 of the Internal Revenue Code, to its employees. On June 7, 2018, the Company’s shareholders approved an amendment and restatement of this plan (this plan, as amended and restated, the “New Plan”), which includes an article that allows the Company to grant restricted shares, restricted share units (“RSU”) and other share-based awards, in addition to stock options. All restricted share, RSU or other share-based award terms and conditions will be specified in future grant agreements. To date, no restricted shares, RSUs or other stock-based awards have been granted. The maximum number of common shares reserved for issuance under the New Plan is 5,686,097, which includes 3,985,768 shares issuable upon exercise of stock 2 019 and All options granted under the New Plan will have an exercise price determined and approved by the Board on the date of the grant, which shall not be less than the market price of the common shares at such time. For the purposes of the New Plan, the market price of a common share shall be the closing sale price of a share on the grant date reported by the stock exchange with the greatest trading volume or, if such day is not a trading day, the closing sale price reported for the immediately preceding trading day. The Company may convert a market price denominated in Canadian dollars into United States dollars and vice versa and such converted amount shall be the market price. An option shall be exercisable during a period established by the Board which shall commence on the date of the grant and shall terminate not later than ten years after the date of the granting of the option. The New Plan provides that the exercise period shall automatically be extended if the date on which it is scheduled to terminate shall fall during a black-out black-out The following table summarizes the Company’s stock options granted in Canadian dollars under the Original Plan and the New Plan: Number Weighted- Weighted- Weighted- Aggregate Aggregate Outstanding, December 31, 2017 2,263,712 14.24 11.35 7.53 1,455 1,160 Granted 326,975 16.51 12.74 Expired (7,908 ) 16.22 12.52 Exercised (94,812 ) 8.81 6.80 Forfeited (41,977 ) 18.09 13.96 Outstanding, December 31, 2018 2,445,990 14.66 10.74 6.99 14,421 10,571 Granted 358,800 22.92 17.14 Expired (1,047 ) 4.75 3.65 Exercised (403,553 ) 12.53 9.46 Forfeited (43,777 ) 18.42 13.91 Outstanding, December 31, 2019 2,356,413 16.21 12.46 6.70 101,404 77,807 December 31, 2019 Exercisable 1,623,284 14.49 11.12 5.89 72,648 55,743 Vested and expected to vest 2,317,044 16.15 12.39 6.67 99,860 76,622 The following table summarizes the Company’s stock options granted in U.S. dollars under the New Plan: Number Weighted- Weighted- Aggregate Outstanding, December 31, 2017 636,595 9.70 9.46 15 Granted 910,783 13.03 Expired — — Exercised — — Forfeited (7,600 ) 9.82 Outstanding, December 31, 2018 1,539,778 11.67 9.02 4,876 Granted 1,501,750 19.89 Expired — — Exercised (126,108 ) 13.32 Forfeited (62,074 ) 14.91 Outstanding, December 31, 2019 2,853,346 15.85 8.66 84,481 December 31, 2019 Exercisable 712,423 11.21 7.66 24,403 Vested and expected to vest 2,738,378 15.79 8.60 81,255 The Company received cash proceeds of $5,498 (C$6,683) (2018: $682 (C$883), 2017: $965 (C$1,250)) from stock options exercised. The stock options expire at various dates from June 30, 2020 to November 7, 2029.A summary of the non-vested Number of Weighted-average Weighted- Non-vested, 899,079 10.25 7.51 Options granted 358,800 14.89 11.42 Options vested (482,042 ) 28.06 21.53 Options forfeited and cancelled (42,708 ) 16.43 12.60 Non-vested, 733,129 16.03 12.30 A summary of the non-vested Number of Weighted- Non-vested, 1,254,428 7.31 Options granted 1,501,750 13.01 Options vested (553,181 ) 7.43 Options forfeited and cancelled (62,074 ) 9.63 Non-vested, 2,140,923 11.21 The estimated fair value of options granted to officers, directors, employees and consultants is amortized over the vesting period. Stock-based compensation expense for equity classified instruments, as well as the financial statement impact of the periodic revaluation of liability classified equity instruments (note 2), is recorded in research and development expenses, general and administration expenses and finance expense (income) as follows: Year Ended December 31, 2019 2018 2017 Research and development expenses: Stock-based compensation for equity classified instruments $ 5,939 $ 2,203 $ 913 Change in fair value of liability classified equity instruments 8,358 2,032 492 $ 14,297 $ 4,235 $ 1,405 General and administrative expenses: Stock-based compensation for equity classified instruments $ 6,737 $ 3,693 $ 1,852 Change in fair value of liability classified equity instruments 27,470 5,362 486 $ 34,207 $ 9,055 $ 2,338 Finance expense (income): Stock-based compensation for equity classified instruments $ — $ 1 $ — Change in fair value of liability classified equity instruments 166 150 (314 ) $ 166 $ 151 $ (314 ) For the year ended December 31, 2019, stock of paid-in paid-in paid-in The estimated fair value of stock options granted in Canadian dollars under the Original Plan and the New Plan was determined using the Black-Scholes option pricing model with the following weighted-average assumptions: Year ended December 31, 2019 2018 2017 Dividend yield 0 % 0 % 0 % Expected volatility 73.59 % 66.25 % 66.25 % Risk-free interest rate 1.47 % 2.18 % 1.44 % Forfeiture rate 5.37 % 5.37 % 4.75 % Expected average life of options 6.05 years 5.91 years 5.90 years The estimated fair value of stock options granted in U.S. dollars under the New Plan was determined using the Black-Scholes option pricing model with the following weighted-average assumptions: Year ended December 31, 2019 2018 2017 Dividend yield 0 % 0 % 0 % Expected volatility 73.15 % 66.78 % 65.89 % Risk-free interest rate 2.23 % 2.69 % 1.84 % Forfeiture rate 5.37 % 5.37 % 4.75 % Expected average life of options 6.03 years 5.88 years 5.89 years Expected Volatility entities of similar complexity and stage of development and calculates historical volatility using the volatility of these companies. Risk-Free Interest Rate Expected Term Share Fair Value The weighted-average Black-Scholes option pricing assumptions for liability classified stock options outstanding at December 31, 2019 and 2018 are as follows: December 31, December 31, Dividend yield 0 % 0 % Expected volatility 76.09 % 72.27 % Risk-free interest rate 1.68 % 1.94 % Forfeiture rate 5.37 % 5.37 % Expected average option term 3.38 years 3.59 years Number of liability classified share options outstanding 1,249,365 1,437,163 The total intrinsic value of stock options exercised during the years ended December 31, 2019, 2018 and 2017 was $9,416, $2,388 and $1,550 respectively. At December 31, 2019, the unamortized compensation expense related to unvested options was $16,720. The remaining unamortized compensation expense as of December 31, 2019 will be recognized over a weighted-average period of 1.8 years. f Employee Stock Purchase Plan: On April 10, 2017, the Company’s shareholders approved an employee stock purchase plan (“ESPP ”) which became effective immediately prior to the consummation of the Company’s IPO. On June 7, 2018, certain amendments to the ESPP were approved by shareholders. Prior to these amendments, the ESPP allowed eligible employees to acquire common shares at a discounted purchase price of 85% of the market value of the Company’s common shares on the purchase date. The ESPP, as amended, allows eligible employees to acquire common shares at a discounted purchase price of the lesser of (i) 85% of the market price of a common share on the first day of the applicable purchase period and (ii) 85% of the market price of a common share on the purchase date. The Company currently holds offerings consisting of a single six-month January and July of each calendar year, with a single purchase date at the end of the purchase period on June and December of each calendar year. Eligible employees are able to contribute up to 15% of their gross base earnings for purchases under the ESPP through regular payroll deductions. Purchases of shares under the ESPP are limited for each employee at $25 thousand As this plan is considered compensatory , the Company recognizes compensation expense on these awards based on their estimated grant date fair value using the Black-Scholes option pricing model. The Company recognizes compensation expense in the consolidated statements of loss and comprehensive loss on a straight-line basis over the requisite service period. For the year ended December 31, 2019, the Company recorded compensation expense of $326 (2018: $114) in research and development expense and general and administrative expense accounts. As of December 31, 2019, total amount contributed by the ESPP participants and not yet settled is $435 (December 31, 2018: $359).

Government Grants and Credits

Government Grants and Credits	12 Months Ended
	Dec. 31, 2019
Government Grants and Credits [Abstract]
Government Grants and Credits	12. Government Grants and Credits Year Ended December 31, 2019 2018 2017 SR&ED credits (expense), net $ 110 $ (5 ) $ 857 IRAP credits — — 218 Total $ 110 $ (5 ) $ 1,075 For the year ended December 31, 2019, the Company recognized refundable investment tax credits of $110 as a reduction of research and development expense. Although the Company has used its best judgment and understanding of the related income tax legislation in determining its claims, it is possible the amounts could increase or decrease materially in the future, as the Canada Revenue Agency and Revenu Québec reserve the right to review and audit the investment tax credit claims. During the current year, the Company did not recognize any amounts under IRAP (the “Industrial Research Assistance Program”). The IRAP funding agreement contains contingency clauses which could require repayment of funding if certain conditions are not met. The Company is in compliance with these conditions.

Research, Collaboration and Lic

Research, Collaboration and Licensing Agreements	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Research, Collaboration and Licensing Agreements	13. Research, Collaboration and Licensing Agreements Revenue recognized from the Company’s strategic partnerships is summarized as follows: Year ended December 31, 2019 2018 2017 Janssen: Recognition of upfront fee $ — $ — $ 50,000 Merck: Milestone revenue 2,000 — — Lilly: Milestone revenue 8,000 2,000 — BMS: Option exercise fee 7,500 4,000 — Daiichi Sankyo: Technology access fee — 18,000 — Milestone revenue — — 1,000 Commercial license option fee 3,500 LEO: Recognition of upfront fee — 5,000 $ — BeiGene: Recognition of upfront fee 3,530 23,530 $ — Iconic: Milestone revenue 1,000 — $ — Research support payments and other payments 4,014 489 762 $ 29,544 $ 53,019 $ 51,762 Contract Assets and Liabilities As at December 31, 2019 and 2018, contract assets from research, collaboration and licensing agreements were $nil and $nil , respectively and contract liabilities were $ and $36,471, respectively. Contract liabilities relate to deferred revenue from the BeiGene agreement described below. 2019 Agreements: License Agreement with Iconic Therapeutics, Inc. (“Iconic”) On May 13, 2019, the Company entered into a license agreement with Iconic to develop and commercialize an antibody-drug conjugate (ICON-2) Pursuant to this agreement, the Company is eligible to receive development and commercial milestone payments and tiered royalties on worldwide net sales. From contract inception to December 31, 2019, the Company has received $1.0 million in milestone payments. This agreement also provides the Company with co-promotion rights with increased royalties for products generated from this collaboration. If Iconic sublicenses the program, in lieu of co-promotion rights, the Company will receive a share of the revenue Iconic receives from any partners as well as tiered royalties on worldwide net sales. 2018 and prior agreements: Research and License Agreement with Merck Sharp & Dohme Research Ltd. (“Merck”) On August 22, 2011, the Company entered into a research and license agreement with Merck, which was amended and restated in December 2014, to develop and commercialize three bispecific antibodies generated through the use of the Company’s Azymetric and EFECT platforms. Under the terms of the agreement, the Company granted Merck a worldwide, royalty-bearing antibody sequence pair exclusive license to research, develop and commercialize certain licensed products. The amendments did not impact the determination of units of accounting or the allocation of the arrangement consideration. Over the life of the agreement, the Company is eligible to receive payments up to $190.75 million, for various license and milestone payments including an upfront payment. From contract inception to December 31, 2019, the Company has received an upfront payment of $1.25 million and research and development related payments totaling $5.5 million. The Company is eligible to receive additional payments for completion of investigational new drug (“IND”) enabling studies of up to $4.0 million, development milestone payments of up to $66.0 million and commercial milestone payments of up to $114.0 million. In addition, the Company is eligible to receive tiered royalties in the low to mid-single These milestone payments were received upon the achievement of certain development activities during the course of the research program and were recorded as revenue upon achievement of the milestone as the Company had no remaining performance obligations under the arrangement. No additional milestone payments or royalties have been received to date. Licensing and Collaboration Agreement with Eli Lilly and Company (“Lilly”) On December 17, 2013, the Company entered into a Licensing and Collaboration Agreement with Lilly to develop novel bispecific antibody therapeutics using the Company’s proprietary Azymetric platform. The Company will apply its Azymetric platform in combination with Lilly’s proprietary targets to create novel bispecific antibodies which Lilly will have the right to develop and commercialize worldwide. The Company is eligible to receive up to $52.0 million for various license and milestone payments. From contract inception to December 31, 2019, the Company has received an upfront payment of $1.0 million and research and development related payments of $3.0 million. The Company is eligible to receive additional development milestone payments of up to $8.0 million and commercial milestone payments of up to $40.0 million. In addition, the Company is eligible to receive tiered royalties in the low to mid-single Lilly was a related party during 2018 but was not considered to be a related party as of December 31, 2018 and thereafter. Licensing and Collaboration Agreement with Lilly On October 22, 2014, the Company entered into a second Licensing and Collaboration Agreement with Lilly to develop novel bispecific antibody therapeutics using the Company’s proprietary Azymetric platform. This agreement did not alter or amend the initial agreement entered into on December 17, 2013. Under the terms of this agreement Lilly was granted a worldwide, royalty-bearing antibody sequence pair-specific license to research, develop and commercialize certain licensed products. Each of the two agreements with Lilly were negotiated independently and the deliverables covered by the respective contracts are unrelated to one another as they cover different product candidates. Accordingly, the second Licensing and Collaboration Agreement with Lilly has been accounted for as a new arrangement. The Company is eligible to receive up to $125.0 million in various license and milestone payments. From contract inception to December 31, 2019, the Company has received research and development related payments totaling $10.0 million. The Company is eligible to receive additional development milestone payments of up to $20.0 million and commercial milestone payments of up to $95.0 million. In addition, the Company is eligible to receive tiered royalties in the low to mid-single digits on product sales. Lilly will have exclusive worldwide commercialization rights to products derived from the collaboration. No license, research, development and commercial milestones or royalty payments have been received to date. The Company determined that other than the research milestone, the events and conditions resulting in payments for development and commercial milestones solely depend on Lilly’s performance. Licensing and Collaboration Agreement with Celgene Corporation & Celgene Alpine Investment Co. LLC (formerly “Celgene” and now a Bristol-Myers Squibb company, “BMS”) On December 23, 2014, the Company entered into an agreement with Celgene (now”BMS”) to develop novel antibody therapeutics using the Company’s proprietary platform. The Company will apply its platform in combination with BMS ’ s proprietary targets to create novel antibodies for which BMS has an option to develop and commercialize a certain number of products (“Commercial License Option”). Upon the execution of the Agreement, the Company received an upfront payment and an expansion fee of $4.0 million. BMS has the right to exercise options on up to ten programs and if BMS opts in on a program, the Company is eligible to receive up to per product candidate (up to $1.64 billion for all ten programs), comprised of a commercial license option payment , development milestone payments of up and commercial milestone payments of up . From contract inception to December 31, 2019, BMS has exercised one commercial license option and the Company has received a total of $7.5 million in product candidate-specific payments. After conclusion of BMS’s research period, BMS will be solely responsible for the research, development, manufacturing and commercialization of the products. In addition, the Company is eligible to receive tiered royalties calculated upon the global net sales of the resulting products. BMS will have exclusive worldwide commercialization rights to products derived from the agreement if BMS elects to exercise a Commercial License Option for each product. The Company determined that, the events and conditions resulting in payments for research, development and commercial milestones solely depend on BMS’s performance. Collaboration and License Agreement with GlaxoSmithKline Intellectual Property Development Ltd. (“GSK”) On December 1, 2015, the Company entered into a Collaboration and License Agreement with GSK for the research, development, and commercialization of novel Fc-engineered At the conclusion of the research collaboration, both GSK and the Company will have the right to develop and commercialize monoclonal and bispecific antibody candidates that incorporate the Company’s optimized immune-modulating Fc domains. Under the terms of the agreement, GSK will have the right to develop a minimum of four products across multiple disease areas, and the Company will be eligible to receive up to $1.1 billion, including research, development, and commercial milestones of up to $110.0 million for each product. In addition, the Company is eligible to receive tiered sales royalties. Under the terms of the agreement, each party is liable for their own internal and external research costs incurred in the project. Furthermore, the Company will have the right to develop up to four products with the intellectual property arising from the collaboration without any royalty or milestone payment to GSK. The Company determined that, the events and conditions resulting in payments for research, development and commercial milestones solely depend on GSK’s performance. No Platform Technology Transfer and License Agreement with GSK On April 21, 2016, the Company entered into a Platform Technology Transfer and License Agreement with GSK for the research, development, and commercialization of novel bispecific antibodies enabled using the Company’s Azymetric platform. Each of the two agreements with GSK were negotiated independently and the deliverables covered by the respective contracts utilize different therapeutic platforms and are unrelated to one another. Accordingly, the Platform Technology and License Agreement with GSK has been accounted for as a new arrangement. In May 2019, this agreement was expanded to provide GSK access to the Company’s unique heavy-light chain pairing technology under the Azymetric platform. This may include bispecific antibodies incorporating new engineered Fc regions generated under the 2015 GSK agreement. The Company is eligible to receive up to $1.1 billion in milestone and other payments. From contract inception to December 31, 2019, the Company has received an upfront technology access fee payment of $6.0 million . The Company is also eligible to receive research milestone payments of up to $37.5 million , development milestone payments of up to $183.5 million and commercial milestone payments of up to $867.0 million . In addition, the Company is entitled to receive tiered royalties on potential sales. The Company determined that, the events and conditions resulting in payments for research, development and commercial milestones solely depend on GSK’s performance. No research, development or commercial milestone payments or royalties have been received to date. Collaboration and Cross License Agreement with Daiichi Sankyo, Co., Ltd. (“Daiichi Sankyo”) On September 26, 2016, the Company entered into a Collaboration and Cross License Agreement with Daiichi Sankyo for the research, development, and commercialization of novel bispecific antibodies enabled using the Company’s Azymetric and EFECT platforms. Additionally, the Company will license immuno-oncology antibodies from Daiichi Sankyo, with the right to research, develop and commercialize multiple products globally in exchange for royalties on product sales. Under the agreement, Daiichi Sankyo will have the option to develop and commercialize a single bispecific immuno-oncology therapeutic. The Company is also eligible to $149.9 million in milestone and other payments. From contract inception to December 31, 2019, the Company has received an upfront technology access fee payment of $2.0 million and research and commercial option related payments totaling $4.5 million. The Company is also eligible to receive additional development milestone payments of up to $63.4 million, and commercial milestone payments of up to $80.0 million. In addition, the Company is eligible to receive tiered royalties ranging from the low single digits up to 10% on product sales. The Company also has non-exclusive non-exclusive Second License Agreement with Daiichi Sankyo In May 2018, the Company entered into a second license agreement with Daiichi Sankyo to research, develop and commercialize two bispecific antibodies generated through the use of the Company’s Azymetric and EFECT platforms. Under the terms of the agreement, the Company granted Daiichi Sankyo a worldwide, royalty-bearing, antibody sequence pair-specific, exclusive license to research, develop and commercialize certain products. Under the agreement, Daiichi Sankyo will be solely responsible for the research, development, manufacturing and commercialization of the products. The Company is also eligible to receive up to $484.7 million in various milestone and other payments. From contract inception to December 31, 2019, the Company received an upfront technology access fee payment of The Company is also eligible to receive development milestone payments totaling up and commercial milestone payments of up to . product-by-product country-by-country No Collaboration and License Agreement with Janssen Biotech, Inc. (“Janssen”) On November 13, 2017, the Company entered into a Collaboration and License Agreement with Janssen to research, develop and commercialize up to six bispecific antibodies generated through the use of the Azymetric and EFECT platforms. Under the terms of the agreement, the Company granted Janssen a worldwide, royalty-bearing, antibody sequence pair-specific exclusive license to research, develop and commercialize certain products. Janssen also has the option to develop two additional bispecific antibodies under this agreement subject to a future option payment. Under the agreement, Janssen will be solely responsible for the research, development, manufacturing and commercialization of the products. The Company is eligible to $1.45 billion in various license and milestone payments. From contract inception to December 31, 2019, the Company has received an upfront payment of $50.0 million. The Company is also eligible to receive development milestone payments of up to $282.0 million and commercial milestone payments of up to $1.12 billion. In addition, Company is eligible to receive tiered royalties in the mid-single product-by-product country-by-country Research and License Agreement with LEO Pharma A/S (“LEO”) On October 23, 2018, the Company entered into a collaboration agreement with LEO. The Company granted LEO a worldwide, royalty-bearing, antibody sequence pair-specific exclusive license to research, develop and commercialize two bispecific antibodies, generated through the use of the Company’s Azymetric and EFECT platforms, for dermatologic indications. The Company will retain rights to develop antibodies resulting from this collaboration in all other therapeutic areas. The Company and LEO are jointly responsible for certain research activities, with the Company’s cost to be fully reimbursed by LEO. Each party is solely responsible for the development, manufacturing, and commercialization of their own products. Pursuant to this agreement, the Company received an upfront payment of $5.0 million in 2018 payments of up to $74.0 million and commercial milestone payments of up to $157.0 million together with tiered royalties on future sales of up to 20% in the United States and up to high single digits elsewhere, and (ii) for the second therapeutic candidate, the Company is eligible to receive preclinical and development milestone payments of up to $86.5 million and commercial milestone payments of up to $157.0 million together with tiered royalties on future sales of up to low double digits globally. For products developed by the Comp any . No Collaboration and License Agreements with BeiGene, Ltd. (“BeiGene”) On November 26, 2018, the Company entered into three concurrent agreements with BeiGene whereby the Company granted BeiGene royalty-bearing exclusive licenses for the research, development and commercialization of its bispecific therapeutic candidates, ZW25 (“ZW25 Agreement”) and ZW49 (“ZW49 Agreement”) in Asia (excluding Japan but including the People’s Republic of China, South Korea and other countries), Australia and New Zealand. In addition, the Company also granted BeiGene a worldwide, royalty-bearing, antibody sequence pair-specific license to research, develop and commercialize globally three bispecific antibodies generated through the use of the Company’s Pursuant to these agreements, t he Company License and Collaboration Agreements for ZW25 and ZW49 The Company is also eligible to receive development and commercial milestone payments of up to $390 million, together with tiered royalties from high single digits and up to 20% on future sales of the products. No development or commercial milestone payments or royalties have been received to date. Under the agreements, the Company and BeiGene are collaborating on certain global clinical studies and both the Companys and BeiGene will be independently conducting clinical studies in their own respective territories. Each of the Company and BeiGene are responsible for all the development and commercialization costs in their own territories. In relation to the ZW25 Agreement, the Company identified the following promised goods and services at the inception of the BeiGene agreement that are material: development and commercial licenses, initial transfer of the Company’s technologies and relevant know-how, sub-committees, sub-committees’ Development and commercial licenses as well as initial transfer of technologies and relevant know-how was two-month sub-committees performance obligations are completed. Remaining deliverables are considered individually distinct and the revenue will be recognized as delivery or transfer of future rights to BeiGene occurs. In relation to the ZW49 Agreement, the Company identified the following promised goods and services at the inception of the BeiGene agreement that are material: development and commercial licenses, initial transfer of the Company’s technologies and relevant know-how, sub-committees, sub-committees’ Development and commercial licenses as well as initial transfer of technologies and relevant know-how sub-committees know-how Phase-1 As of December , , the Company recorded of the ZW and ZW agreements as deferred revenue on the Company’s consolidated balance sheet : $ 36,471 ). Amounts not expected to be recognized as revenue within the next twelve months of the consolidated balance sheet date are classified as long-term deferred revenue. Research and Licensing Agreement for Azymetric and EFECT Platforms For the development and commercialization licenses of up to three bispecific antibody therapeutics using the Company’s mid-single

Other expense, net

Other expense, net	12 Months Ended
	Dec. 31, 2019
Other Income and Expenses [Abstract]
Other expense, net	14. Other expense, net Other expenses consist of the following: Year ended December 31, 2019 2018 2017 Foreign exchange (loss) gain $ (567 ) $ 72 $ 97 Change in fair value of warrant liabilities (note 10) — (3,565 ) 2,450 Loss on debt extinguishment (note 10) — — (3,114 ) Accretion expense — — (248 ) Other (173 ) (166 ) (422 ) $(740) $(3,659) $(1,237)

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	15. Income Taxes a. Income tax (expense) recovery is comprised of the following: Year Ended December 31, 2019 2018 2017 Current income tax expense $ (1,373 ) $ (2,188 ) $ (429 ) Deferred income tax recovery (expense) 1,955 17 (15 ) Income tax recovery (expense) $ 582 $ (2,171 ) $ (444 ) Current income tax expense for the years ended December 31, 2019, 2018 and 2017 arose from the operations of Zymeworks Biopharmaceuticals Inc., the Company’s wholly owned subsidiary in the United States, and from the withholding taxes paid by the Company abroad in 2019, 2018 and 2017. b. Income tax expense (recovery) varies from the amounts that would be computed by applying the expected Canadian income tax rate of 27% (2018: 27%, 2017: 26%) to loss before income taxes as shown in the following tables: Year Ended December 31, 2019 2018 2017 Computed taxes at Canadian tax rate $ 39,453 $ 9,284 $ 2,587 Non-deductible (13,020 ) (4,311 ) (259 ) Difference between domestic and foreign tax rate 104 14 11 Effect of change in tax rates (10 ) (2 ) 860 Adjustments to prior year (39 ) (543 ) 313 Change in valuation allowance (29,057 ) (9,340 ) (8,510 ) Share issuance costs in equity 3,578 1,906 2,547 Change in recognition and measurement of tax positions (2,391 ) (672 ) — Changes due to SR&ED 2,200 1,668 1,973 Other (236 ) (175 ) 34 Income tax recovery (expen se) $ 582 $ (2,171 ) $ (444 ) c. Deferred income tax assets and liabilities result from the temporary differences between the amounts of assets and liabilities recognized for financial statement and income tax purposes. The significant components of the deferred income tax assets and liabilities are as follows: December 31, December 31, Deferred tax assets: Non-capital $ 33,016 $ 6,680 Deferred revenue 8,894 9,848 Share issue costs 5,473 3,428 Property and equipment 1,731 1,167 Research and development deductions and credits 21,813 20,749 Contingent consideration 264 191 Stock options 1,242 220 Operating lease liability 1,540 — Other 348 314 $ 74,321 $ 42,597 Deferred tax liabilities: Property and equipment (583 ) (54 ) IPR&D (4,760 ) (4,967 ) Operating lease right-of-use assets (1,016 ) — Other (408 ) (132 ) $ (6,767 ) $ (5,153 ) 67,554 37,444 Less: valuation allowance (66,744 ) (37,360 ) Net deferred tax assets (liabilities) $ 810 $ 84 Deferred tax asset $ 1,218 $ 198 Deferred tax liability (408 ) (114 ) Net deferred tax assets (liability) $ 810 $ 84 The realization of deferred income tax assets is dependent upon the generation of sufficient taxable income during future periods in which the temporary differences are expected to reverse. The valuation allowance is reviewed on a quarterly basis and if the assessment of the “more likely than not” criterion changes, the valuation allowance is adjusted accordingly. d. At December 31, 2019, the Company has net operating losses carried forward for tax purposes in Canada, which are available to reduce taxable income of future years of approximately $122.3 million (December 31, 2018: $24.7 million) expiring commencing 2035 through 2039. At December 31, 2019, the Company also has unclaimed tax deductions for scientific research and experimental development expenditures of approximately $58.2 million ( December 31, December 31, e. The investment tax credits and non-capital Expiry date Investment tax credits Non-capital 2029 1,078 — 2030 — — 2031 — — 2032 — — 2033 — — 2034 230 — 2035 1,068 3,961 2036 878 24,578 2037 1,587 10,625 Expiry date Investment tax credits Non-capital 2038 1,485 — 2039 1,749 83,117 $ 8,075 $ 122,281 f. A reconciliation of total unrecognized tax benefits for the years ended December 31, 2019, 2018, and 2017 are as follows: Year Ended December 31, 2019 2018 2017 Balance, beginning of year $ 672 $ — $ — Increases related to prior year tax positions — 142 — Increases related to current year tax positions 2,391 530 — Balance, end of year $ 3,063 $ 672 $ — Included in the balance of unrecognized tax benefits at December 31, 2019 and 2018 are potential benefits of $nil that, if recognized, would affect the effective tax rate on income from continuing operations. Recognition of these potential benefits would result in a deferred tax asset in the form of net operating loss carry-forward, which would be subject to a valuation allowance based on conditions existing at the reporting date. The Company recognizes interest expense and penalties related to unrecognized tax benefits within the provision for income tax expense on the consolidated statements of loss and comprehensive loss. The Company currently files income tax returns in Canada and the U . . s the Company has

Leases

Leases	12 Months Ended
	Dec. 31, 2019
Text Block [Abstract]
Leases	16. Leases The Company leases separate office and laboratory space in Vancouver, British Columbia, with terms of each lease expiring in August 2021 right-of-use The balance sheet classification of the Company’s lease liabilities was as follows: December 31, December 31, Operating lease liabilities: Current portion $ 1,282 $ — Long-term portion 5,599 — Total operating lease liabilities 6,881 $ — Finance lease liabilities: Current portion included in other current liabilities 10 15 Long-term portion included in other long-term liabilities 46 42 Total finance lease liabilities 56 57 Total lease liabilities $ 6,937 $ 57 Lease payments for the year ended December 31, 2019 were $1.6 million and have been included in net cash provided by operating activities in the consolidated statement of cash flows. As of December 31, 2019, the future minimum lease payments of the Company’s operating lease liabilities were as follows: Operating Within 1 year $ 1,438 1 to 2 years 2,076 2 to 3 years 1,007 3 to 4 years 991 4 to 5 years 1,019 Thereafter 781 Total operating lease payments 7,312 Less: Imputed interest (431 ) Operating lease liabilities $ 6,881 As of December 31, 2019, the weighted average remaining lease term is 4.3 years and the discount rate used to determine the operating lease liability was 4.6% for leases in Canadian dollar s s During the year c The Company also leases office equipment under finance lease agreements. As of December 31, 2019, the future minimum lease payments of the Company’s finance lease liabilities were as follows: Finance leases Within 1 year $ 31 1 to 2 years 16 2 to 3 years 6 3 to 4 years 3 4 to 5 years 1 Thereafter — Total finance lease payments 57 Less: Imputed interest (1 ) Finance lease liabilities $ 56

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2019
Investments, All Other Investments [Abstract]
Financial Instruments	17. Financial Instruments The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level of classification each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the fair value hierarchy. Fair Value Measurements The Company measures certain financial instruments and other items at fair value. To determine fair value, the Company uses a fair value hierarchy that prioritizes the inputs, assumptions and valuation techniques used to measure fair value. The three levels of the fair value hierarchy are as follows: • Level 1 inputs are unadjusted quoted market prices for identical instruments available in active markets. • Level 2 inputs are inputs other than Level 1 prices, such as prices for similar asset or liability that are observable either directly or indirectly. If the asset or liability has a contractual term, the input must be observable for substantially the full term. An example includes quoted market prices for similar assets or liabilities in active markets. • Level 3 inputs are unobservable inputs for the asset or liability and will reflect management’s assessment Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company’s financial instruments consist of cash and cash equivalents, short-term investments, amounts receivable, accounts payable and accrued liabilities, finance and operating lease obligations, liability classified stock options and other long-term liabilities. The carrying values of cash and cash equivalents, short-term investments, amounts receivable and accounts payable and accrued liabilities approximate their fair values due to the immediate or short-term maturity of these financial instruments. As quoted prices for the liability classified stock options are not readily available, the Company has use s The following tables present information about the Company’s liabilities that are measured at fair value on a recurring basis, and indicate the fair value hierarchy of the valuation techniques used to determine such fair value: December 31, Level 1 Level 2 Level 3 Liabilities Liability classified stock options $ 45,569 $ — $ — $ 45,569 Liability for contingent consideration 978 — — 978 Total $ 46,547 $ — $ — $ 46,547 December 31, Level 1 Level 2 Level 3 Liabilities Liability classified stock options $ 12,603 $ — $ — $ 12,603 Liability for contingent consideration 707 — — 707 Total $ 13,310 $ — $ — $ 13,310 The following table presents the changes in fair value of the Company’s liability for contingent consideration: Liability at Increase (decrease) in Liability at end of the period Year ended December 31, 2019 $ 707 $ 271 $ 978 Year ended December 31, 2018 $ 470 $ 237 $ 707 The following table presents the changes in fair value of the Company’s warrant liabilities: Liability at Reclassification Increase (decrease) in Exercise of Liability at end of the period Year ended December 31, 2019 $ — $ — $ — $ — $ — Year ended December 31, 2018 $ 1,348 $ — $ 3,565 $ (4,913 ) $ — The following table presents the changes in fair value of liability classified stock options: Liability at Reclassification Increase (decrease) in Exercise of Unrealized foreign Liability at end of the period Year ended December 31, 2019 $ 12,603 $ 119 $ 35,994 $ (3,804 ) $ 657 $ 45,569 Year ended December 31, 2018 $ 3,945 $ — $ 9,451 $ (142 ) $ (651 ) $ 12,603 The change in fair value of liability classified stock options for the period is presented within research and development expenses and general and administrative expenses. Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents, short-term investments and accounts receivable. Cash and cash equivalents and short-term investments are invested in accordance with the Company’s Treasury Policy with the primary objective being the preservation of capital and maintenance of liquidity. The Treasury Policy includes guidelines on the quality of financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. The Company limits its exposure to credit loss by placing its cash and cash equivalents and short-term investments with high credit quality financial institutions. The Company does not currently maintain a provision for bad debts on accounts receivable. At December 31, 2019, the maximum exposure to credit risk for accounts receivable was $2.2 million (December 31, 2018: $0.4 million) and all account receivables are due within the next 12 months. Liquidity Risk Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company’s short-term cash requirements are primarily to settle its financial liabilities, which consist primarily of accounts payable and accrued liabilities falling due within 45 days and current portion of lease obligations falling due within the next 12 months, with medium term requirements to invest in property and equipment and research and development. The Company’s principal sources of liquidity to settle its financial liabilities are cash, cash equivalents and short-term investment, collection of accounts receivable relating to research collaboration and license agreements and additional public equity offerings as required. The Company believes that these principal sources of liquidity are sufficient to fund its operations for at least the next 12 months. Foreign Currency Risk The Company incurs certain operating expenses in currencies other than the U.S. dollar and accordingly The operating results and financial position of the Company are reported in U.S. dollars in the Company’s consolidated financial statements. The fluctuation of the U.S. dollar relative to the Canadian dollar and other foreign currencies will have an impact on the reported balances for net assets, net loss and shareholders’ equity in the Company’s consolidated financial statements.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	18. Commitments and Contingencies The Company has entered into research collaboration agreements with strategic partners in the ordinary course of operations that may include contractual milestone payments related to the achievement of pre-specified In connection with the Kairos acquisition, the Company may be required to make future payments to CDRD Ventures Inc. (“CVI”) upon the direct achievement of certain development milestones for products incorporating certain Kairos intellectual property, as well as royalty payments on the net sales of such products. For out-licensed mid-single In , the Company entered into a license agreement with Innovative Targeting Solutions Inc., (“ITS”), to use ITS’ protein engineering technology for the development and commercialization of antibody and protein therapeutics. Pursuant to the agreement, the Company agreed to pay an aggregate of $ million in annual licensing fees to ITS over a , the full outstanding amount of which was paid in the period ended December , in accordance with the prepayment terms thereunder. As a result, as of December , , th e Company ha d further licensing fee payment obligations under the agreement. Licensing fees paid to ITS are recorded as over their estimated useful lives. The Company may also be required to make payments to ITS upon the achievement of certain development and commercial milestones, as well as royalty payments on net sales. No liabilities have been recorded for any amounts payable as of December , . Contingencies From time to time, the Company may be subject to various legal proceedings and claims related to matters arising in the ordinary course of business. The Company does not believe it is currently subject to any material matters where there is at least a reasonable possibility that a material loss may be incurred.

Subsequent event

Subsequent event	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent events	19 On January 27 closed public offering pursuant to which the Company sold common shares , common shares to the underwriters upon their full exercise of their over-allotment option , at $46.50 per common share and pre-funded warrants in lieu of common shares at $46.4999 per pre-funded warrant. Net proceeds were approximately $ million, after underwriting discounts, commissions and offering expenses.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). The consolidated financial statements include the accounts of Zymeworks Inc. and its wholly owned subsidiar y on All amounts expressed in the consolidated financial statements of the Company and the accompanying notes thereto are expressed in thousands of U.S. dollars, except for share and per share data and where otherwise indicated. References to “$” are to U.S. dollars and references to “C$” are to Canadian dollars. Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.
Foreign Currency	Foreign Currency The functional currency of the Company is the U.S. dollar. Transactions denominated in foreign currencies are translated at the approximate exchange rate prevailing on the date of the transaction. At period end, monetary assets and liabilities denominated in foreign currencies are translated into U.S. dollars using exchange rates in effect at the balance sheet date. Resulting foreign exchange gains and losses are reflected in the Consolidated Statements of Loss and Comprehensive Loss.
Use of Estimates	Use of Estimates The preparation of the financial statements in accordance with U.S. GAAP requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, some of which are those related to revenue recognition including estimated timing of completion of performance obligations required to meet revenue recognition criteria, accrual of expenses including clinical and preclinical
Revenue Recognition	Revenue Recognition Effective January 1, 2018, the Company adopted on a modified retrospective basis Accounting Standards Codification Topic 606, Revenue from Contracts with Customers The Company applied ASC 606 to all arrangements to date. For collaborative arrangements that fall within the scope of ASC 808, Collaborative Arrangements (“ASC 808”), the Company applies the revenue recognition model under ASC 606 to part or all of the arrangement, when deemed appropriate. In accordance with ASC 606, the Company recognizes revenue when the Company’s customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised deliverables in the contract; (ii) determination of whether the promised deliverables are performance obligations including whether they are distinct; (iii) measurement of the transaction price, including uncertainties related to variable consideration; (iv) allocation of the transaction price to the performance obligations based on the stand-alone selling prices; and (v) recognition of revenue when or as the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration that it is entitled to in exchange for the goods and services transferred to the customer. At contract inception, the Company assesses the goods or services promised within each contract that falls under the scope of Topic 606, to identify distinct performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. The Company has entered into a number of collaboration and licensing agreements. Promised deliverables within these agreements may include: (i) grants of licenses, or options to obtain licenses, to the Company’s intellectual property, (ii) research and development services, (iii) drug product manufacturing, and (iv) participation on joint research and/or development committees. The terms of these agreements typically include one or more of the following types of payments to the Company: • non-refundable, • research, development and regulatory milestone payments; • research support payments; and • royalties and commercial milestone payments. If the expectation at contract inception is such that the period between payment by the licensee and the completion of related performance obligations will be one year or less, the Company assumes that the contract does not have a significant financing component. When applying the revenue recognition criteria of ASC 606 to license and collaboration agreements, the Company may be required to apply significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining when performance obligations have been met, assessing the recognition and future reversal of variable consideration, and determining and applying appropriate methods of measuring progress for performance obligations satisfied over time. These judgments are discussed in more detail in the following paragraphs for each type of payment received by the Company under the terms of the license and collaborations agreements. Non-refundable, If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, non-refundable, Research, development and regulatory milestone payments At the inception of each arrangement that includes research, development or regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. When it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates catch-up Research and development milestones in the Company’s collaboration agreements may include some, but not necessarily all, of the following types of events: • completion of preclinical research and development work leading to selection of product candidates; • initiation of Phase 1, Phase 2 and Phase 3 clinical trials; and • achievement of certain other technical, scientific or development criteria. Regulatory milestone payments may include the following types of events: • filing of regulatory applications for marketing approval in the United States, Europe or Japan, including Investigational New Drug (“IND”) applications and Biologics License Application (“BLA”); and • marketing approval in major markets, such as the United States, Europe or Japan. Research support and other payments Payments by the licensees in exchange for research activities performed by the Company on behalf of the licensee are recognized as revenue upon performance of such activities at rates consistent with prevailing market rates. Payments for research supplies provided are recognized as revenue upon delivery of the supplies. Royalties and commercial milestone payments For arrangements that include sales-based royalties, including commercial milestone payments based on pre-specified
Contract assets and liabilities	Contract Assets and Liabilities Contract assets are mainly comprised of trade receivables net of allowance for doubtful debts, which includes amounts billed and currently due from customers. Contract liabilities are mainly comprised of deferred revenues. Amounts received prior to satisfying all revenue recognition criteria are recorded as deferred revenue in the Company’s consolidated financial statements. Amounts not expected to be recognized as revenue within the next twelve months of the consolidated balance sheet date are classified as long-term deferred revenue.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of 90 days or less at the date of acquisition to be cash equivalents. Cash and cash equivalents consist primarily of money market funds and are recorded at cost, which approximates fair value.
Short-Term Investments	Short-Term Investments The Company’s short-term investments consist of guaranteed investment certificates and term deposits with original maturities exceeding three months and less than one year. The investments are recorded at cost plus accrued interest, which approximates their fair value.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable a nd Allowance for Doubtful Accoun ts Accounts receivable are recorded at invoiced amounts, net of any allowance for doubtful accounts. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in existing accounts receivable. The Company evaluates the collectability of accounts receivable on a regular basis based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. There is no allowance for doubtful accounts recorded as at December 31, 2019 and 2018.
Deferred Financing Costs	Deferred Financing Fees Deferred financing fees amount s upon closing of such tra nsaction.
Segment Information	Segment Information The Company operates and manages its business in one segment, which is the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance.
Property and Equipment	Property and Equipment Property and equipment are recorded at cost net of accumulated depreciation. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in earnings. Repairs and maintenance costs are expensed as incurred. The Company records depreciation using the straight-line method over the estimated useful lives of the property and equipment as follows: Asset Class Rate Computer hardware 3 Office equipment 3 Furniture and fixtures 5 Laboratory equipment 7 Leasehold improvements Shorter of the initial lease term or useful life Property and equipment acquired or disposed of during the year are depreciated proportionately for the period they are in use.
Patents and Intellectual Property Costs	Patents and Intellectual Property Costs Costs incurred to acquire patents and to prosecute and maintain intellectual property rights are expensed as incurred to general and administrative expense due to the uncertainty surrounding the drug development process and the uncertainty of future benefits. Patents and intellectual property acquired from third parties are capitalized and amortized over the remaining life of the patent, if related to fo r the underlying technol ogy
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company assesses the recoverability of its long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or group of assets. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset or asset group. Assets classified as held for sale are reported at the lower of the carrying amount or fair value, less costs to sell. As of December 31, 2019 and 2018, the Company determined that there were no impairments of long-lived assets and no assets held-for-sale.
Government Grants and Credits	Government Grants and Credits Government grants are recognized where there is reasonable assurance that the grant will be received and all associated conditions will be complied with. Reimbursements of eligible research and development expenditures pursuant to government assistance programs are recorded as reductions of research and development costs when the related costs have been incurred and there is reasonable assurance regarding collection of the claim. Grant claims not settled by the balance sheet date are recorded as receivables, provided their receipt is reasonably assured. The determination of the amount of the claim, and hence the receivable amount, requires management to make calculations based on its interpretation of eligible expenditures in accordance with the terms of the programs. The reimbursement claims submitted by the Company are subject to review by the relevant government agencies. The Company has used its best judgment and understanding of the related program agreements in determining the receivable amount. The Company participates in SR&ED and Research Tax Credit Programs, two federal tax incentive programs that encourage Canadian and U.S. businesses to conduct research and development in Canada and in U.S. respectively. The benefits of investment tax credits for scientific research and development expenditures are recognized in the year the qualifying expenditure is made provided there is reasonable assurance of recoverability. These investment tax credits are recorded as reductions to research and development expenditures.
Research and Development Costs	Research and Development Costs Research and development costs are expensed as incurred and include costs that the Company incurs for its own and for the Company’s strategic partners’ research and development activities. These costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations on the Company’s behalf, investigative sites and consultants that conduct the Company’s clinical trials, the cost of acquiring and manufacturing clinical trial materials and other allocated expenses, stock-based
Clinical Trial Expense Accruals	Clinical Trial Expense Accruals Clinical trial expenses represent a significant component of research and development expenses and the Company outsources a significant portion of these activities to third party contract research organizations. Third-party clinical trial expenses include investigator fees, site costs, clinical research organization costs and other trial-related vendor costs. As part of preparing the
Income Taxes	Income Taxes The Company accounts for income taxes using an asset and liability approach. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The measurement of deferred tax assets is reduced, if necessary, by the extent of a valuation allowance. The recognition of uncertain tax positions is evaluated based on whether it is considered more likely than not that the position taken, or expected to be taken, on a tax return will be sustained upon examination through litigation or appeal. For those positions that meet the recognition criteria, they are measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement. Interest and tax penalties are expensed as incurred.
Stock-Based Compensation	Stock-Based Compensation The Company recognizes stock-based compensation expense on equity and liability classified stock-based awards granted to employees, directors, and certain consultants. The Company measures the cost of such awards based on the fair value of the award, net of estimated forfeitures, and recognizes stock-based compensation expense in the consolidated statements of loss and comprehensive loss on a straight-line basis over the requisite service period. The requisite service period generally equals the vesting period of the awards. The fair values of the awards are estimated using the Black-Scholes option pricing model which uses various inputs including estimated fair value of the Company’s underlying common share at the grant date, expected term, estimated volatility, risk-free interest rate and expected dividend yields of the Company’s common shares. The Company applies an estimated forfeiture rate derived from historical employee termination behavior. If the actual number of forfeitures differs from those estimated by management, adjustments to compensation expense may be required in future periods. Equity classified awards are measured using their grant date fair value. Liability classified awards are initially measured using their grant date fair value and are subsequently remeasured at fair value at each balance sheet date until exercised or cancelled, with changes in fair value recognized as compensation cost (ASC 718 awards) or additional paid-in Awards accounted for under Accounting Standards Codification (“ASC”) 718 “Compensation—Stock Options” (“ASC 718”), with an exercise price which is not denominated in: (a) the currency of a market in which a substantial portion of the Company’s equity securities trades, (b) the currency in which the individual’s pay is denominated, or (c) the Company’s functional currency, are required to be classified as liabilities. For awards accounted for under ASC 815 “Derivatives and Hedging” (“ASC 815”), any warrant or option that provides for an exercise price which is not denominated in the Company’s functional currency is required to be classified as a liability. Certain option awards which were classified as equity on grant dates were subsequently reclassified to liability: • Upon the change of the compensation currency for certain executives from Canadian dollars to U.S. dollars effective January 1, 2017 held by such executives which were previously classified as equity awards per ASC 718 on January 1, 2017 have been reclassified as liability awards of which $2,879 was reclassified from additional paid-in capital and the remaining $4,492 was recorded to the statement of loss on January 1, 2017 as under ASC 718 statement of loss • Upon the change of the compensation currency for a certain executive from Canadian dollars to U.S. dollars effective January 1, paid-in The Company has an employee stock purchase plan which is considered compensatory. Accordingly, the Company recognizes compensation expense on these awards based on their estimated grant date fair value using the Black-Scholes option pricing model. The Company recognizes compensation expense in the consolidated statements of loss and comprehensive loss on a straight-line basis over the requisite service period.
Business Combination and Goodwill	Business Combinations and Goodwill Business combinations are accounted for using the acquisition method. The fair value of total purchase consideration is allocated to the fair values of identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount being classified as goodwill. All assets, liabilities and contingent liabilities acquired or assumed in a business combination are recorded at their fair values at the date of acquisition. If the Company’s interest in the fair value of the acquiree’s net identifiable assets exceeds the cost of the acquisition, the excess is recognized in earnings or loss immediately. Transaction costs that are incurred in connection with a business combination, other than costs associated with the issuance of debt or equity securities, are expensed as incurred. Goodwill is evaluated for impairment on an annual basis or more frequently if an indicator of impairment is present (note 6). As part of the impairment evaluation, the Company may elect to perform an assessment of qualitative factors. If this qualitative assessment indicates that it is more likely than not that the fair value of the reporting unit that includes the goodwill is less than its carrying value, then a quantitative impairment test would be prepared to compare the fair value to the carrying value and record an impairment charge if the carrying value exceeds the fair value.
Acquired In-Process Research and Development and Definite-lived Intangible Assets	Acquired In-Process Acquired IPR&D represents the fair value assigned to research and development assets that have not reached technological feasibility. IPR&D is classified as an indefinite-lived intangible asset and is not amortized. IPR&D becomes definite-lived upon the completion or abandonment of the associated research and development efforts. All research and development costs incurred subsequent to the acquisition of IPR&D are expensed as incurred. Indefinite-lived intangible assets are evaluated for impairment on an annual basis or more frequently if an indicator of impairment is present. Definite-lived intangible assets include computer software and a research license and are amortized on a basis which reflects the pattern in which the economic benefits are consumed. Amortization begins when the assets are put into use. If there is a event indicating that the carrying value of a definte-lived intangible asset may be impaired, then the Company will perform an impairment test. When an impairment test is performed, if the carrying value exceeds the recoverable value, based on the sum of undiscounted future cash flows, then such asset is written down to its fair value.
Net Loss Per Share	Net loss per share Basic net loss per share attributable to common shareholders is computed by dividing the net loss attributable to common shareholders by the weighted average number of common shares outstanding for the year. Diluted net loss per share attributable to common shareholders is computed by adjusting net loss attributable to common shareholders to reallocate undistributed earnings based on the potential impact of dilutive securities, including outstanding redeemable convertible Class A preferred shares, stock options and warrants. Diluted net loss per share attributable to common shareholders is computed by dividing the diluted net loss attributable to common shareholders by the weighted-average number of common shares outstanding for the year, including potential dilutive common shares assuming the dilutive effect of outstanding instruments. The if-converted

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Schedule of Estimated Useful Lives	The Company records depreciation using the straight-line method over the estimated useful lives of the property and equipment as follows: Asset Class Rate Computer hardware 3 Office equipment 3 Furniture and fixtures 5 Laboratory equipment 7 Leasehold improvements Shorter of the initial lease term or useful life

Recent Accounting Pronounceme_2

Recent Accounting Pronouncements (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Changes and Error Corrections [Abstract]
Schedule of Impact on Company's Balance Sheet Due to Adoption of Accounting Pronouncements	The impact of the adoption of Topic 842 on the accompanying c b s December 31, Adjustments January 1, Operating lease right-of-use (1) $ — $ 3,222 $ 3,222 Total lease inducements (2) 333 (333 ) — Total operating lease liabilities (3) — 3,561 3,561 (1) Right-of-use Right-of-use (2) Included in current and long-term other liabilities (note 9) (3) Includes current and non-current As reported Effect of Balances Operating expenses for the year ended December 31, 2019 $ 180,845 $ 311 $ 180,534

Net Loss per Share (Tables)

Net Loss per Share (Tables)	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Summary of Calculation of Diluted Loss Per Share	Net loss per share for the years ended December 31, 2019, 2018 and 2017 was as follows: Year Ended December 31, 2019 2018 2017 Numerator Net loss attributable to common shareholders: $ (145,437 ) $ (36,556 ) $ (10,406 ) Deemed dividend due to beneficial conversion feature — — (520 ) Basic $ (145,437 ) $ (36,556 ) $ (10,926 ) Adjustment for change in fair value of ASC 815 liability classified stock options and warrant — — (2,757 ) Diluted $ (145,437 ) $ (36,556 ) $ (13,683 ) Denominator: Weighted-average common shares outstanding: Basic (*) 38,022,014 29,089,896 21,249,414 Adjustment for dilutive effect of liability classified stock options and warrants — — 71,795 Diluted 38,022,014 29,089,896 21,321,209 Net loss per common share – basic $ (3.83 ) $ (1.26 ) $ (0.51 ) Net loss per common share – diluted $ (3.83 ) $ (1.26 ) $ (0.64 ) (*): Weighted average number of common shares used in the basic earnings per share calculation for the year ended December 31, 2019 includes the pre-funded

IPR&D and Goodwill (Tables)

IPR&D and Goodwill (Tables)	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Carrying Value of IPR&D, Net of Impairment	The following table summarizes the carrying value of IPR&D, net of impairment: Acquired IPR&D Accumulated Net Balance at December 31, 2016 $ 20,700 $ (768 ) $ 19,932 Change during the period — (1,536 ) (1,536 ) Balance at December 31, 2017 $ 20,700 $ (2,304 ) $ 18,396 Change during the period — — — Balance at December 31, 2018 $ 20,700 $ (2,304 ) $ 18,396 Change during the period — (768 ) (768 ) Balance at December 31, 2019 $ 20,700 $ (3,072 ) $ 17,628

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Components of Property and Equipment	Property and equipment consist of the following: December 31, 2019 2018 Computer hardware $ 2,438 $ 1,439 Furniture and fixtures 1,248 747 Office equipment 729 535 Laboratory equipment 6,628 5,270 Leasehold improvements 6,374 3,377 Construction in progress 915 221 Property and equipment $ 18,332 $ 11,589 Less accumulated depreciation (7,232 ) (5,105 ) Property and equipment, net $ 11,100 $ 6,484

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets consist of the following: December 31, 2019 2018 Computer software and research $ 12,985 $ 5,429 Less accumulated amortization (6,928 ) (3,815 ) Intangible assets, net $ 6,057 $ 1,614

Liabilities (Tables)

Liabilities (Tables)	12 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Expenses	Accounts payable and accrued liabilities consist of the following: December 31, 2019 2018 Trade payables $ 5,349 $ 2,599 Accrued research expenses 24,262 6,633 Employee compensation and vacation accruals 5,009 2,926 Accrued legal and professional fees 231 556 Other 840 689 Total $ 35,691 $ 13,403
Schedule of Other Long-term Liabilities	Other long term liabilities consisted of the following: December 31, 2019 2018 Liability for contingent consideration (note 18 $ 978 $ 707 Lease inducements — 197 Finance lease liability (note 1 6 46 42 Total $ 1,024 $ 946

Payment of long-term debt and_2

Payment of long-term debt and exercise of liability classified warrants (Tables)	12 Months Ended
	Dec. 31, 2019
Text Block [Abstract]
Summary of Debt	Year ended December 31, Long term debt at January 1, 2017 $ 4,810 Less: unamortized debt issue costs at January 1, 2017 (393 ) Long term debt at January 1, 2017, net of deferred charges $ 4,417 Accretion during the period up to the Repayment Date 248 Amortization of debt issue costs during the period up to the Repayment Date 35 Carrying value of long term debt on the Repayment Date, net of deferred charges $ 4,700 Repayment, including repayment premium and expenses (7,814 ) Loss on debt extinguishment $ (3,114 )

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2019
Summary of Stock Options Granted	The following table summarizes the Company’s stock options granted in Canadian dollars under the Original Plan and the New Plan: Number Weighted- Weighted- Weighted- Aggregate Aggregate Outstanding, December 31, 2017 2,263,712 14.24 11.35 7.53 1,455 1,160 Granted 326,975 16.51 12.74 Expired (7,908 ) 16.22 12.52 Exercised (94,812 ) 8.81 6.80 Forfeited (41,977 ) 18.09 13.96 Outstanding, December 31, 2018 2,445,990 14.66 10.74 6.99 14,421 10,571 Granted 358,800 22.92 17.14 Expired (1,047 ) 4.75 3.65 Exercised (403,553 ) 12.53 9.46 Forfeited (43,777 ) 18.42 13.91 Outstanding, December 31, 2019 2,356,413 16.21 12.46 6.70 101,404 77,807 December 31, 2019 Exercisable 1,623,284 14.49 11.12 5.89 72,648 55,743 Vested and expected to vest 2,317,044 16.15 12.39 6.67 99,860 76,622
Schedule of Non-Vested Stock Option Activity	A summary of the non-vested Number of Weighted-average Weighted- Non-vested, 899,079 10.25 7.51 Options granted 358,800 14.89 11.42 Options vested (482,042 ) 28.06 21.53 Options forfeited and cancelled (42,708 ) 16.43 12.60 Non-vested, 733,129 16.03 12.30 A summary of the non-vested Number of Weighted- Non-vested, 1,254,428 7.31 Options granted 1,501,750 13.01 Options vested (553,181 ) 7.43 Options forfeited and cancelled (62,074 ) 9.63 Non-vested, 2,140,923 11.21
Schedule of Stock-based Compensation Expense for Equity Classified Instruments	Stock-based compensation expense for equity classified instruments, as well as the financial statement impact of the periodic revaluation of liability classified equity instruments (note 2), is recorded in research and development expenses, general and administration expenses and finance expense (income) as follows: Year Ended December 31, 2019 2018 2017 Research and development expenses: Stock-based compensation for equity classified instruments $ 5,939 $ 2,203 $ 913 Change in fair value of liability classified equity instruments 8,358 2,032 492 $ 14,297 $ 4,235 $ 1,405 General and administrative expenses: Stock-based compensation for equity classified instruments $ 6,737 $ 3,693 $ 1,852 Change in fair value of liability classified equity instruments 27,470 5,362 486 $ 34,207 $ 9,055 $ 2,338 Finance expense (income): Stock-based compensation for equity classified instruments $ — $ 1 $ — Change in fair value of liability classified equity instruments 166 150 (314 ) $ 166 $ 151 $ (314 )
U.S. dollars under the New Plan [Member]
Summary of Stock Options Granted	The following table summarizes the Company’s stock options granted in U.S. dollars under the New Plan: Number Weighted- Weighted- Aggregate Outstanding, December 31, 2017 636,595 9.70 9.46 15 Granted 910,783 13.03 Expired — — Exercised — — Forfeited (7,600 ) 9.82 Outstanding, December 31, 2018 1,539,778 11.67 9.02 4,876 Granted 1,501,750 19.89 Expired — — Exercised (126,108 ) 13.32 Forfeited (62,074 ) 14.91 Outstanding, December 31, 2019 2,853,346 15.85 8.66 84,481 December 31, 2019 Exercisable 712,423 11.21 7.66 24,403 Vested and expected to vest 2,738,378 15.79 8.60 81,255
Employee Stock Option [Member]
Schedule of Estimated Fair Value of Stock Options Assumptions	The estimated fair value of stock options granted in Canadian dollars under the Original Plan and the New Plan was determined using the Black-Scholes option pricing model with the following weighted-average assumptions: Year ended December 31, 2019 2018 2017 Dividend yield 0 % 0 % 0 % Expected volatility 73.59 % 66.25 % 66.25 % Risk-free interest rate 1.47 % 2.18 % 1.44 % Forfeiture rate 5.37 % 5.37 % 4.75 % Expected average life of options 6.05 years 5.91 years 5.90 years
Liability Classified Stock Options [Member]
Schedule of Estimated Fair Value of Stock Options Assumptions	The weighted-average Black-Scholes option pricing assumptions for liability classified stock options outstanding at December 31, 2019 and 2018 are as follows: December 31, December 31, Dividend yield 0 % 0 % Expected volatility 76.09 % 72.27 % Risk-free interest rate 1.68 % 1.94 % Forfeiture rate 5.37 % 5.37 % Expected average option term 3.38 years 3.59 years Number of liability classified share options outstanding 1,249,365 1,437,163
New Stock Option Plan [Member]
Schedule of Estimated Fair Value of Stock Options Assumptions	The estimated fair value of stock options granted in U.S. dollars under the New Plan was determined using the Black-Scholes option pricing model with the following weighted-average assumptions: Year ended December 31, 2019 2018 2017 Dividend yield 0 % 0 % 0 % Expected volatility 73.15 % 66.78 % 65.89 % Risk-free interest rate 2.23 % 2.69 % 1.84 % Forfeiture rate 5.37 % 5.37 % 4.75 % Expected average life of options 6.03 years 5.88 years 5.89 years

Government Grants and Credits (

Government Grants and Credits (Tables)	12 Months Ended
	Dec. 31, 2019
Text Block [Abstract]
Component of Government Grants and Credits	Year Ended December 31, 2019 2018 2017 SR&ED credits (expense), net $ 110 $ (5 ) $ 857 IRAP credits — — 218 Total $ 110 $ (5 ) $ 1,075

Research, Collaboration and L_2

Research, Collaboration and Licensing Agreements (Tables)	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Revenue Recognized from Strategic Partnerships	Revenue recognized from the Company’s strategic partnerships is summarized as follows: Year ended December 31, 2019 2018 2017 Janssen: Recognition of upfront fee $ — $ — $ 50,000 Merck: Milestone revenue 2,000 — — Lilly: Milestone revenue 8,000 2,000 — BMS: Option exercise fee 7,500 4,000 — Daiichi Sankyo: Technology access fee — 18,000 — Milestone revenue — — 1,000 Commercial license option fee 3,500 LEO: Recognition of upfront fee — 5,000 $ — BeiGene: Recognition of upfront fee 3,530 23,530 $ — Iconic: Milestone revenue 1,000 — $ — Research support payments and other payments 4,014 489 762 $ 29,544 $ 53,019 $ 51,762

Other expense, net (Tables)

Other expense, net (Tables)	12 Months Ended
	Dec. 31, 2019
Other Income and Expenses [Abstract]
Schedule of Other Nonoperating Income (Expense)	Other expenses consist of the following: Year ended December 31, 2019 2018 2017 Foreign exchange (loss) gain $ (567 ) $ 72 $ 97 Change in fair value of warrant liabilities (note 10) — (3,565 ) 2,450 Loss on debt extinguishment (note 10) — — (3,114 ) Accretion expense — — (248 ) Other (173 ) (166 ) (422 ) $(740) $(3,659) $(1,237)

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of Income Tax Expense (Recovery)	Income tax (expense) recovery is comprised of the following: Year Ended December 31, 2019 2018 2017 Current income tax expense $ (1,373 ) $ (2,188 ) $ (429 ) Deferred income tax recovery (expense) 1,955 17 (15 ) Income tax recovery (expense) $ 582 $ (2,171 ) $ (444 )
Schedule of Effective Income Tax Rate Reconciliation	Income tax expense (recovery) varies from the amounts that would be computed by applying the expected Canadian income tax rate of 27% (2018: 27%, 2017: 26%) to loss before income taxes as shown in the following tables: Year Ended December 31, 2019 2018 2017 Computed taxes at Canadian tax rate $ 39,453 $ 9,284 $ 2,587 Non-deductible (13,020 ) (4,311 ) (259 ) Difference between domestic and foreign tax rate 104 14 11 Effect of change in tax rates (10 ) (2 ) 860 Adjustments to prior year (39 ) (543 ) 313 Change in valuation allowance (29,057 ) (9,340 ) (8,510 ) Share issuance costs in equity 3,578 1,906 2,547 Change in recognition and measurement of tax positions (2,391 ) (672 ) — Changes due to SR&ED 2,200 1,668 1,973 Other (236 ) (175 ) 34 Income tax recovery (expen se) $ 582 $ (2,171 ) $ (444 )
Schedule of Significant Components of the Deferred Income Tax Assets and Liabilities	The significant components of the deferred income tax assets and liabilities are as follows: December 31, December 31, Deferred tax assets: Non-capital $ 33,016 $ 6,680 Deferred revenue 8,894 9,848 Share issue costs 5,473 3,428 Property and equipment 1,731 1,167 Research and development deductions and credits 21,813 20,749 Contingent consideration 264 191 Stock options 1,242 220 Operating lease liability 1,540 — Other 348 314 $ 74,321 $ 42,597 Deferred tax liabilities: Property and equipment (583 ) (54 ) IPR&D (4,760 ) (4,967 ) Operating lease right-of-use assets (1,016 ) — Other (408 ) (132 ) $ (6,767 ) $ (5,153 ) 67,554 37,444 Less: valuation allowance (66,744 ) (37,360 ) Net deferred tax assets (liabilities) $ 810 $ 84 Deferred tax asset $ 1,218 $ 198 Deferred tax liability (408 ) (114 ) Net deferred tax assets (liability) $ 810 $ 84
Schedule of Expiry Details of Investment Tax Credits, Non-Capital Losses and Net Operating Losses for Income Tax Purposes	The investment tax credits and non-capital Expiry date Investment tax credits Non-capital 2029 1,078 — 2030 — — 2031 — — 2032 — — 2033 — — 2034 230 — 2035 1,068 3,961 2036 878 24,578 2037 1,587 10,625 Expiry date Investment tax credits Non-capital 2038 1,485 — 2039 1,749 83,117 $ 8,075 $ 122,281
Schedule of Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits	A reconciliation of total unrecognized tax benefits for the years ended December 31, 2019, 2018, and 2017 are as follows: Year Ended December 31, 2019 2018 2017 Balance, beginning of year $ 672 $ — $ — Increases related to prior year tax positions — 142 — Increases related to current year tax positions 2,391 530 — Balance, end of year $ 3,063 $ 672 $ —

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2019
Text Block [Abstract]
Schedule of Balance Sheet Classification of Lease Liabilities	The balance sheet classification of the Company’s lease liabilities was as follows: December 31, December 31, Operating lease liabilities: Current portion $ 1,282 $ — Long-term portion 5,599 — Total operating lease liabilities 6,881 $ — Finance lease liabilities: Current portion included in other current liabilities 10 15 Long-term portion included in other long-term liabilities 46 42 Total finance lease liabilities 56 57 Total lease liabilities $ 6,937 $ 57
Schedule of Maturities of Operating Lease Liabilities	As of December 31, 2019, the future minimum lease payments of the Company’s operating lease liabilities were as follows: Operating Within 1 year $ 1,438 1 to 2 years 2,076 2 to 3 years 1,007 3 to 4 years 991 4 to 5 years 1,019 Thereafter 781 Total operating lease payments 7,312 Less: Imputed interest (431 ) Operating lease liabilities $ 6,881
Schedule of Maturities of Finance Lease Liabilities	The Company also leases office equipment under finance lease agreements. As of December 31, 2019, the future minimum lease payments of the Company’s finance lease liabilities were as follows: Finance leases Within 1 year $ 31 1 to 2 years 16 2 to 3 years 6 3 to 4 years 3 4 to 5 years 1 Thereafter — Total finance lease payments 57 Less: Imputed interest (1 ) Finance lease liabilities $ 56

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2019
Investments, All Other Investments [Abstract]
Schedule of Financial Liabilities Measured at Fair Value on a Recurring Basis	The following tables present information about the Company’s liabilities that are measured at fair value on a recurring basis, and indicate the fair value hierarchy of the valuation techniques used to determine such fair value: December 31, Level 1 Level 2 Level 3 Liabilities Liability classified stock options $ 45,569 $ — $ — $ 45,569 Liability for contingent consideration 978 — — 978 Total $ 46,547 $ — $ — $ 46,547 December 31, Level 1 Level 2 Level 3 Liabilities Liability classified stock options $ 12,603 $ — $ — $ 12,603 Liability for contingent consideration 707 — — 707 Total $ 13,310 $ — $ — $ 13,310
Summary of Changes in Fair Value of the Company's Liability for Contingent Consideration	The following table presents the changes in fair value of the Company’s liability for contingent consideration: Liability at Increase (decrease) in Liability at end of the period Year ended December 31, 2019 $ 707 $ 271 $ 978 Year ended December 31, 2018 $ 470 $ 237 $ 707
Schedule of Changes in Fair Value of Warrant Liabilities	The following table presents the changes in fair value of the Company’s warrant liabilities: Liability at Reclassification Increase (decrease) in Exercise of Liability at end of the period Year ended December 31, 2019 $ — $ — $ — $ — $ — Year ended December 31, 2018 $ 1,348 $ — $ 3,565 $ (4,913 ) $ —
Schedule of Changes in Fair Value of Liability Classified Stock Options	The following table presents the changes in fair value of liability classified stock options: Liability at Reclassification Increase (decrease) in Exercise of Unrealized foreign Liability at end of the period Year ended December 31, 2019 $ 12,603 $ 119 $ 35,994 $ (3,804 ) $ 657 $ 45,569 Year ended December 31, 2018 $ 3,945 $ — $ 9,451 $ (142 ) $ (651 ) $ 12,603

Nature of Operations - Addition

Nature of Operations - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2019
Date of incorporation	Sep. 8, 2003

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail) $ in Thousands	Jan. 01, 2019USD ($)	Jan. 01, 2017USD ($)	Dec. 31, 2019USD ($)Segmentprogramme	Dec. 31, 2018USD ($)
Schedule Of Accounting Policies [Line Items]
Number of Operating Segments | Segment			1
Allowance for doubtful accounts			$ 0	$ 0
federal tax incentive [Member]
Schedule Of Accounting Policies [Line Items]
no of operating programms | programme			2
Executive Officer [Member]
Schedule Of Accounting Policies [Line Items]
Equity awards reclassified as liability awards	$ 240	$ 7,371
Additional paid in capital reclassified as liability awards	119	2,879
Equity awards reclassified as loss	$ 121	$ 4,492

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Estimated Useful Lives (Detail)	12 Months Ended
	Dec. 31, 2019
Computer hardware [Member]
Property, Plant and Equipment [Line Items]
Property and equipment estimated useful lives	3 years
Office equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment estimated useful lives	3 years
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment estimated useful lives	5 years
Laboratory equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment estimated useful lives	7 years
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment estimated useful lives	Shorter of the initial lease term or useful life

Recent Accounting Pronounceme_3

Recent Accounting Pronouncements - Impact of the Adoption of Topic 842 On Balance Sheet (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Operating lease right-of-use assets	$ 5,400	$ 3,222
Total lease inducements			$ 333
Total operating lease liabilities	$ 6,881	3,561
Adjustments Due To The Adoption Of Topic 842 [Member]
Operating lease right-of-use assets		3,222
Total lease inducements		(333)
Total operating lease liabilities		$ 3,561

Recent Accounting Pronounceme_4

Recent Accounting Pronouncements - The impact of the Adoption of Topic 842 on the Accompanying Condensed Consolidated Statements of Operations (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Operating expenses	$ 180,845	$ 86,383	$ 61,230
Effect Of Adoption Of Topic 842 [Member]
Operating expenses	311
Balances Without Adoption Of Topic 842 [Member]
Operating expenses	$ 180,534

Net Loss per Share - Summary of

Net Loss per Share - Summary of Calculation of Diluted Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
		Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Net loss attributable to common shareholders:
Net loss attributable to common shareholders		$ (145,437)	$ (36,556)	$ (10,406)
Deemed dividend due to beneficial conversion feature				(520)
Basic		(145,437)	(36,556)	(10,926)
Adjustment for change in fair value of ASC 815 liability classified stock options and warrant				(2,757)
Diluted		$ (145,437)	$ (36,556)	$ (13,683)
Weighted-average common shares outstanding:
Basic	[1]	38,022,014	29,089,896	21,249,414
Adjustment for dilutive effect of liability classified stock options and warrants				71,795
Diluted		38,022,014	29,089,896	21,321,209
Net loss per common share – basic		$ (3.83)	$ (1.26)	$ (0.51)
Net loss per common share – diluted		$ (3.83)	$ (1.26)	$ (0.64)
[1]	Weighted average number of common shares used in the basic earnings per share calculation for the three and nine months ended December 31, 2019 includes the pre-funded warrants issued in connection with the Company’s June 2019 offering as the warrants are exercisable at any time and for nominal cash consideration.

Short-term Investments - Additi

Short-term Investments - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2019
Short-Term Investments [Line Items]
Short-term investments maturity term	12 months
Minimum [Member]
Short-Term Investments [Line Items]
Short-term investments interest rate	2.00%
Maximum [Member]
Short-Term Investments [Line Items]
Short-term investments interest rate	3.00%

IPR&D and Goodwill - Additional

IPR&D and Goodwill - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2017
Acquired Indefinite-lived Intangible Assets [Line Items]
Impairment of intangible assets	$ 768	$ 1,536
IPR&D [Member]
Acquired Indefinite-lived Intangible Assets [Line Items]
Impairment of intangible assets	768	$ 1,536
Valuation Allowance, Deferred Tax Asset, Increase	$ 207

IPR&D and Goodwill - Summary of

IPR&D and Goodwill - Summary of Carrying Value of IPR&D, Net of Impairment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Acquired Indefinite-lived Intangible Assets [Line Items]
Beginning balance	$ 18,396	$ 18,396	$ 19,932
Change during the period	(768)		(1,536)
Ending balance	17,628	18,396	18,396
IPR&D [Member]
Acquired Indefinite-lived Intangible Assets [Line Items]
Acquired IPR&D, beginning balance	20,700	20,700	20,700
Acquired IPR&D, Change during the period
Acquired IPR&D, ending balance	20,700	20,700	20,700
Beginning balance	(2,304)	(2,304)	(768)
Change during the period	(768)		(1,536)
Ending balance	$ (3,072)	$ (2,304)	$ (2,304)

Property and Equipment - Compon

Property and Equipment - Components of Property and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Property and equipment	$ 18,332	$ 11,589
Less accumulated depreciation	(7,232)	(5,105)
Property and equipment, net	11,100	6,484
Computer hardware [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	2,438	1,439
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	1,248	747
Office equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	729	535
Laboratory equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	6,628	5,270
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	6,374	3,377
Construction in progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 915	$ 221

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Capital lease	$ 84	$ 72
Accumulated depreciation for the asset	70	56
Total future minimum lease payments	57	62
Depreciation expense	2,312	1,880	$ 1,681
Office equipment [Member]
Property, Plant and Equipment [Line Items]
Capital lease	$ 12	$ 10

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Computer software and research license	$ 12,985	$ 5,429
Less accumulated amortization	(6,928)	(3,815)
Intangible assets, net	$ 6,057	$ 1,614

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense on intangible assets	$ 3,113	$ 1,750	$ 1,058

Liabilities - Schedule of Accou

Liabilities - Schedule of Accounts Payable and Accrued Expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Accounts Payable and Accrued Liabilities, Current [Abstract]
Trade payables	$ 5,349	$ 2,599
Accrued research expenses	24,262	6,633
Employee compensation and vacation accruals	5,009	2,926
Accrued legal and professional fees	231	556
Other	840	689
Total	$ 35,691	$ 13,403

Liabilities - Schedule of Other

Liabilities - Schedule of Other Long-term Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Other Liabilities, Noncurrent [Abstract]
Liability for contingent consideration (note 18)	$ 978	$ 707
Lease inducements	0	197
Finance lease liability (note 16)	46	42
Total	$ 1,024	$ 946

Payment of long-term debt and_3

Payment of long-term debt and exercise of liability classified warrants - Perceptive Debt - Additional Information (Detail) $ / shares in Units, $ in Thousands	Jun. 06, 2017USD ($)	Apr. 28, 2017$ / sharesshares	Jun. 02, 2016USD ($)$ / sharesshares	Jun. 06, 2017USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Jun. 24, 2019$ / shares	Jun. 04, 2018shares	May 10, 2018shares
Line of Credit Facility [Line Items]
Warrants issued to purchase shares | shares		398,076
Warrants exercise price | $ / shares		$ 8.67					$ 0.0001
Conversion of redeemable convertible class A preferred share warrants into common share warrants		1.349367-for-1 basis
Conversion ratio		1.349367
Repayment of debt (note 10)						$ (7,814)
Accretion expense						248
Amortization of debt issue costs						35
Increase (decrease) in fair value of warrants					$ 3,565	$ (2,450)
Perceptive Warrants [Member]
Line of Credit Facility [Line Items]
Warrants issued to purchase shares | shares								220,000	178,076
Common stock issued upon exercise of warrants | shares								126,880	79,481
Increase (decrease) in fair value of warrants					$ 3,565
Perceptive Debt [Member]
Line of Credit Facility [Line Items]
Credit facility			$ 15,000
Debt principal balance	$ 7,500			$ 7,500
Repayment of debt (note 10)	(7,814)
Early repayment premium	300
Legal fees	$ 14
Interest expense				360
Accretion expense				248
Amortization of debt issue costs				$ 35
Redeemable Convertible Class A Preferred Shares [Member]
Line of Credit Facility [Line Items]
Warrants issued to purchase shares | shares			295,009
Warrants exercise price | $ / shares			$ 11.69
Warrants expiry term			5 years
Redeemable Convertible Class A Preferred Shares [Member] | Warrant liabilities [Member]
Line of Credit Facility [Line Items]
Conversion ratio			1.349367
Tranche A Term Loans [Member]
Line of Credit Facility [Line Items]
Net proceeds received			$ 6,953
Tranche A Term Loans [Member] | Perceptive Debt [Member]
Line of Credit Facility [Line Items]
Credit facility			7,500
Tranche B Term Loans [Member] | Perceptive Debt [Member]
Line of Credit Facility [Line Items]
Credit facility			$ 7,500

Payment of long-term debt and_4

Payment of long-term debt and exercise of liability classified warrants - Summary of Debt (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Jan. 01, 2017
Debt Instruments [Abstract]
Long term debt at January 1, 2017		$ 4,810
Less: unamortized debt issue costs at January 1, 2017		(393)
Long term debt at January 1, 2017, net of deferred charges		$ 4,417
Accretion during the period up to the Repayment Date	$ 248
Amortization of debt issue costs during the period up to the Repayment Date	35
Carrying value of long term debt on the Repayment Date, net of deferred charges	4,700
Repayment, including repayment premium and expenses	(7,814)
Loss on debt extinguishment	$ (3,114)

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Detail) $ / shares in Units, $ in Thousands, $ in Thousands	Jun. 24, 2019USD ($)$ / sharesshares	Jun. 11, 2018USD ($)$ / sharesshares	Jun. 07, 2018	May 31, 2017shares	May 03, 2017USD ($)$ / sharesshares	Apr. 28, 2017USD ($)$ / sharesshares	Jul. 14, 2006	Dec. 31, 2019CAD ($)shares	Dec. 31, 2019USD ($)shares	Dec. 31, 2018CAD ($)shares	Dec. 31, 2018USD ($)shares	Dec. 31, 2017CAD ($)shares	Dec. 31, 2017USD ($)shares	Dec. 31, 2028	Dec. 21, 2015shares
Temporary Equity [Line Items]
Redeemable convertible preferred shares, authorized															6,413,265
Convertible preferred stock outstanding						5,260,404
Share issued price per share | $ / shares						$ 13
Conversion of preferred stock to common stock						7,098,194
Share conversion ratio						1.349367
Beneficial conversion feature | $						$ 520
Preferred stock, shares issued									0		0
Preferred stock, shares outstanding									0		0
Unamortized compensation expense related to unvested options | $									$ 16,720
Remaining unamortized compensation expense, weighted-average period								1 year 9 months 18 days	1 year 9 months 18 days
Warrant exercise price | $ / shares	$ 0.0001					$ 8.67
Stock-based compensation | $									$ 12,676		$ 3,876		$ 4,827
Number of shares issuable upon exercise of outstanding warrents						398,076
underwriting discounts, commissions and offering expenses | $					$ 9,400
Common Shares [Member]
Temporary Equity [Line Items]
Conversion of preferred stock to common stock												7,098,194	7,098,194
Number of shares issued								7,013,892	7,013,892	6,210,000	6,210,000	4,894,467	4,894,467
Offering [Member]
Temporary Equity [Line Items]
Share issued price per share | $ / shares	18	$ 15.75
Warrants issued price per pre funded warrant | $ / shares	$ 17.9999
Number of shares issued	7,013,892
Number of shares issued	7,013,892	6,210,000
Net proceeds from issuance | $ | $	$ 188,000	$ 90,800
underwriting discounts, commissions and offering expenses | $	$ 13,200	$ 7,100
Over-Allotment Option [Member]
Temporary Equity [Line Items]
Pre funded warrants issued in lieu of common shares to underwriters	4,166,690
Number of shares issued to underwriters	1,458,336	810,000		394,467
IPO [Member]
Temporary Equity [Line Items]
Number of shares issued					4,894,467
Share issued, price per share | $ / shares					$ 13
Net proceeds from issuance | $ | $					$ 54,200
Original Stock Option Plan [Member]
Temporary Equity [Line Items]
Shares granted with respect to maximum fixed amount equal, percentage							20.00%
Shares available for issuance under the Original Plan vesting period							4 years
New Stock Option Plan [Member]
Temporary Equity [Line Items]
Proceeds from stock options exercised								$ 6,683	$ 5,498	$ 883	$ 682	$ 1,250	$ 965
Option exercised intrinsic value | $									$ 9,416		$ 2,388		$ 1,550
U.S Dollar Under the New Option Stock Plan [Member]
Temporary Equity [Line Items]
Shares granted with respect to maximum fixed amount equal, percentage			20.00%
Maximum number of common shares reserved for issuance											5,686,097
Shares issuable upon exercise of stock options											3,985,768
Maximum number of common shares reserved for issuance increase in percentage														4.00%
Employees Stock Purchase Plan [Member]
Temporary Equity [Line Items]
Share-based compensation arrangement by share-based payment award, plan modification, description and terms								On June 7, 2018, certain amendments to the ESPP were approved by shareholders. Prior to these amendments, the ESPP allowed eligible employees to acquire common shares at a discounted purchase price of 85% of the market value of the Company’s common shares on the purchase date. The ESPP, as amended, allows eligible employees to acquire common shares at a discounted purchase price of the lesser of (i) 85% of the market price of a common share on the first day of the applicable purchase period and (ii) 85% of the market price of a common share on the purchase date. The ESPP qualifies as an “employee stock purchase plan” within the meaning of Section 423 of the Code for employees who are United States taxpayers.	On June 7, 2018, certain amendments to the ESPP were approved by shareholders. Prior to these amendments, the ESPP allowed eligible employees to acquire common shares at a discounted purchase price of 85% of the market value of the Company’s common shares on the purchase date. The ESPP, as amended, allows eligible employees to acquire common shares at a discounted purchase price of the lesser of (i) 85% of the market price of a common share on the first day of the applicable purchase period and (ii) 85% of the market price of a common share on the purchase date. The ESPP qualifies as an “employee stock purchase plan” within the meaning of Section 423 of the Code for employees who are United States taxpayers.
Maximum eligible employees contribution under ESPP									15.00%
Purchase of shares under ESPP, maximum limit for each employee | $									$ 25
Total amount contributed by ESPP participants | $									435		$ 359
Compensation charge | $									$ 326		$ 114
Director [Member]
Temporary Equity [Line Items]
Shares available for issuance under the Original Plan vesting period							3 years

Shareholders' Equity - Summary

Shareholders' Equity - Summary of Stock Options Granted (Detail) $ / shares in Units, $ / shares in Units, $ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019CAD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018CAD ($)$ / sharesshares	Dec. 31, 2018CAD ($)$ / sharesshares	Dec. 31, 2017CAD ($)$ / sharesshares	Dec. 31, 2017CAD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Granted	358,800	358,800
Canadian Dollar Under the New Option Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding, Beginning balance	2,445,990	2,445,990	2,263,712	2,263,712
Number of Options, Granted	358,800	358,800	326,975	326,975
Number of Options, Expired	(1,047)	(1,047)	(7,908)	(7,908)
Number of Options, Exercised	(403,553)	(403,553)	(94,812)	(94,812)
Number of Options, Forfeited	(43,777)	(43,777)	(41,977)	(41,977)
Number of Options Outstanding, Ending balance	2,356,413	2,356,413	2,445,990	2,445,990	2,263,712	2,263,712
Number of Options, Exercisable	1,623,284						1,623,284
Number of Options, Vested and expected to vest	2,317,044						2,317,044
Weighted-Average Exercise Price, Outstanding, Beginning balance | (per share)	$ 14.66	$ 10.74	$ 14.24	$ 11.35
Weighted-Average Exercise Price, Granted | (per share)	22.92	17.14	16.51	12.74
Weighted-Average Exercise Price, Expired | (per share)	4.75	3.65	16.22	12.52
Weighted-Average Exercise Price, Exercised | (per share)	12.53	9.46	8.81	6.80
Weighted-Average Exercise Price, Forfeited | (per share)	18.42	13.91	18.09	13.96
Weighted-Average Exercise Price, Outstanding, Ending balance | (per share)	$ 16.21	$ 12.46	$ 14.66	$ 10.74	$ 14.24	$ 11.35
Weighted-Average Contractual Term, Outstanding	6 years 8 months 12 days	6 years 8 months 12 days	6 years 11 months 26 days	6 years 11 months 26 days	7 years 6 months 10 days	7 years 6 months 10 days
Aggregate intrinsic value Outstanding	$ 101,404		$ 14,421	$ 14,421	$ 1,455	$ 1,455	$ 77,807	$ 10,571	$ 1,160
Weighted-Average Exercise Price, Exercisable | (per share)	$ 14.49	$ 11.12
Weighted-Average Exercise Price, Vested and expected to vest | (per share)	$ 16.15						$ 12.39
Weighted-Average Contractual Term, Exercisable	5 years 10 months 20 days	5 years 10 months 20 days
Aggregate intrinsic value Exercisable	$ 72,648	$ 55,743
Weighted-Average Contractual Term, Vested and expected to vest	6 years 8 months 1 day	6 years 8 months 1 day
Aggregate intrinsic value Vested and expected to vest | $	$ 99,860
Vested and expected to vest | $							$ 76,622
U.S Dollar Under the New Option Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding, Beginning balance	1,539,778	1,539,778	636,595	636,595
Number of Options, Granted	1,501,750	1,501,750	910,783	910,783
Number of Options, Expired	0	0
Number of Options, Exercised	(126,108)	(126,108)	0	0
Number of Options, Forfeited	(62,074)	(62,074)	(7,600)	(7,600)
Number of Options Outstanding, Ending balance	2,853,346	2,853,346	1,539,778	1,539,778	636,595	636,595
Number of Options, Exercisable	712,423						712,423
Number of Options, Vested and expected to vest	2,738,378						2,738,378
Weighted-Average Exercise Price, Outstanding, Beginning balance | $ / shares		$ 11.67		$ 9.70
Weighted-Average Exercise Price, Granted | $ / shares		19.89		13.03
Weighted-Average Exercise Price, Expired | $ / shares		0
Weighted-Average Exercise Price, Exercised | $ / shares		13.32		0
Weighted-Average Exercise Price, Forfeited | $ / shares		14.91		9.82
Weighted-Average Exercise Price, Outstanding, Ending balance | $ / shares		$ 15.85		$ 11.67		$ 9.70
Weighted-Average Contractual Term, Outstanding	8 years 7 months 28 days	8 years 7 months 28 days	9 years 7 days	9 years 7 days	9 years 5 months 15 days	9 years 5 months 15 days
Aggregate intrinsic value Outstanding | $							$ 84,481	$ 4,876	$ 15
Weighted-Average Exercise Price, Exercisable | $ / shares		$ 11.21
Weighted-Average Exercise Price, Vested and expected to vest | $ / shares							$ 15.79
Weighted-Average Contractual Term, Exercisable	7 years 7 months 28 days	7 years 7 months 28 days
Aggregate intrinsic value Exercisable | $		$ 24,403
Weighted-Average Contractual Term, Vested and expected to vest	8 years 7 months 6 days	8 years 7 months 6 days
Aggregate intrinsic value Vested and expected to vest | $							$ 81,255

Shareholders' Equity - Schedule

Shareholders' Equity - Schedule of Non-Vested Stock Option Activity (Detail)	12 Months Ended
	Dec. 31, 2019$ / sharesshares	Dec. 31, 2019$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options, Non-vested,Beginning balance	899,079	899,079
Number of Options granted	358,800	358,800
Number of Options vested	(482,042)	(482,042)
Number of Options forfeited and cancelled	(42,708)	(42,708)
Number of options, Non-vested,Ending balance	733,129	733,129
Weighted- average fair value price, Non-vested,Beginning balance | (per share)	$ 10.25	$ 7.51
Weighted- average fair value price, Options granted | (per share)	14.89	11.42
Weighted- average fair value price, Options vested | (per share)	28.06	21.53
Weighted- average fair value price, Options forfeited and cancelled | (per share) | (per share)	16.43	12.60
Weighted- average fair value price, Non-vested,Ending balance | (per share)	$ 16.03	$ 12.30
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options, Non-vested,Beginning balance	1,254,428	1,254,428
Number of Options granted	1,501,750	1,501,750
Number of Options vested	(553,181)	(553,181)
Number of Options forfeited and cancelled	(62,074)	(62,074)
Number of options, Non-vested,Ending balance	2,140,923	2,140,923
Weighted- average fair value price, Non-vested,Beginning balance | $ / shares		$ 7.31
Weighted- average fair value price, Options granted | $ / shares		13.01
Weighted- average fair value price, Options vested | $ / shares		7.43
Weighted- average fair value price, Options forfeited and cancelled | (per share) | $ / shares		9.63
Weighted- average fair value price, Non-vested,Ending balance | $ / shares		$ 11.21

Shareholders' Equity - Schedu_2

Shareholders' Equity - Schedule of Stock-based Compensation Expense for Equity Classified Instruments (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
General and administrative expenses	$ 64,177	$ 29,457	$ 18,550
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation for equity classified instruments	5,939	2,203	913
Change in fair value of liability classified equity instruments	8,358	2,032	492
Research and development expenses	14,297	4,235	1,405
General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation for equity classified instruments	6,737	3,693	1,852
Change in fair value of liability classified equity instruments	27,470	5,362	486
General and administrative expenses	34,207	9,055	2,338
Finance Expense (Income) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation for equity classified instruments	0	1
Change in fair value of liability classified equity instruments	166	150	(314)
Finance expenses	$ 166	$ 151	$ (314)

Shareholders' Equity - Schedu_3

Shareholders' Equity - Schedule of Estimated Fair Value of Stock Options Assumptions (Detail) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%	0.00%
Expected volatility	73.59%	66.25%	66.25%
Risk-free interest rate	1.47%	2.18%	1.44%
Forfeiture rate	5.37%	5.37%	4.75%
Expected average life of options	6 years 18 days	5 years 10 months 28 days	5 years 10 months 24 days
Liability Classified Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%
Expected volatility	76.09%	72.27%
Risk-free interest rate	1.68%	1.94%
Forfeiture rate	5.37%	5.37%
Expected average life of options	3 years 4 months 17 days	3 years 7 months 2 days
Number of share options outstanding	1,249,365	1,437,163
U.S Dollar Under the New Option Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%	0.00%
Expected volatility	73.15%	66.78%	65.89%
Risk-free interest rate	2.23%	2.69%	1.84%
Forfeiture rate	5.37%	5.37%	4.75%
Expected average life of options	6 years 10 days	5 years 10 months 17 days	5 years 10 months 20 days
Number of share options outstanding	2,853,346	1,539,778	636,595

Government Grants and Credits -

Government Grants and Credits - Component of Government Grants and Credits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Movement Of Allowance For Finance Lease Receivables [Line Items]
Government grants and credits	$ 110	$ (5)	$ 1,075
Scientific Research And Experimental Development Tax Credit (Expense) [Member]
Movement Of Allowance For Finance Lease Receivables [Line Items]
Government grants and credits	$ 110	$ (5)	857
IRAP Credits [Member]
Movement Of Allowance For Finance Lease Receivables [Line Items]
Government grants and credits			$ 218

Government Grants and Credits_2

Government Grants and Credits - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Receivables [Abstract]
Accrued refundable investment tax credits	$ 110

Research, Collaboration and L_3

Research, Collaboration and Licensing Agreements - Schedule Of Collaborative Arrangements and Noncollaborative Arrangement Transactions (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized	$ 29,544	$ 53,019	$ 51,762
Research support payments and other payments [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized	4,014	489	762
Janssen Biotech, Inc. [Member] | Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized			50,000
Bei Gene [Member] | Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized	3,530	23,530
Eli Lilly and Company [Member] | Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized	8,000	2,000
Daiichi Sankyo, Co., Ltd [Member] | Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized		18,000
Daiichi Sankyo, Co., Ltd [Member] | Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized			$ 1,000
Daiichi Sankyo, Co., Ltd [Member] | Commercial License Option Exercise [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized	3,500
LEO Pharma [Member] | Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized		5,000
Merck Sharp and Dohme Research Ltd. [Member] | Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized	2,000
Iconic Therapeutics Inc [Member] | Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized	1,000
BMS [Member] | Option Exercise Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue recognized	$ 7,500	$ 4,000

Research, Collaboration and L_4

Research, Collaboration and Licensing Agreements - Additional Information - Merck (Detail) - USD ($)	Dec. 31, 2019	Aug. 22, 2011	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2019
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities	$ 32,941		$ 32,941	$ 36,471		$ 32,941
Revenue			29,544,000	53,019,000	$ 51,762,000
Contract assets	0		0	$ 0		0
Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			0
Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			$ 0
Merck Sharp & Dohme Research Ltd. [Member] | Research Support Payments [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue						5,500,000
Merck Sharp & Dohme Research Ltd. [Member] | Research and License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Eligible to Receive [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 190,750,000
Merck Sharp & Dohme Research Ltd. [Member] | Research and License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Eligible to Receive [Member] | Maximum [Member] | Investigational New Drug [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	4,000,000
Merck Sharp & Dohme Research Ltd. [Member] | Research and License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Eligible to Receive [Member] | Maximum [Member] | Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	66,000,000
Merck Sharp & Dohme Research Ltd. [Member] | Research and License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Eligible to Receive [Member] | Maximum [Member] | Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 114,000,000
Merck Sharp & Dohme Research Ltd. [Member] | Research and License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue						$ 1,250,000

Research, Collaboration and L_5

Research, Collaboration and Licensing Agreements - Additional Information - Lilly (Detail) - USD ($)	Dec. 31, 2019	Dec. 17, 2013	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2019
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			$ 29,544,000	$ 53,019,000	$ 51,762,000
Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			0
Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			$ 0
Eli Lilly and Company [Member] | Research Support Payments [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue						$ 3,000,000
Eli Lilly and Company [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Eligible to Receive [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment		$ 52,000,000
Eli Lilly and Company [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Eligible to Receive [Member] | Maximum [Member] | Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment	$ 8,000,000
Eli Lilly and Company [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Eligible to Receive [Member] | Maximum [Member] | Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment	$ 40,000,000
Eli Lilly and Company [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue						$ 1,000,000

Research, Collaboration and L_6

Research, Collaboration and Licensing Agreements - Additional Information - Lilly Two (Detail) - USD ($)	Dec. 31, 2019	Oct. 22, 2014	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2019
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			$ 29,544,000	$ 53,019,000	$ 51,762,000
Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			0
Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			$ 0
Eli Lilly and Company [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Project Two [Member] | Research and Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue						$ 10,000,000
Eli Lilly and Company [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Project Two [Member] | Eligible to Receive [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 125,000,000
Eli Lilly and Company [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Project Two [Member] | Eligible to Receive [Member] | Maximum [Member] | Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 20,000,000
Eli Lilly and Company [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Project Two [Member] | Eligible to Receive [Member] | Maximum [Member] | Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 95,000,000

Research, Collaboration and L_7

Research, Collaboration and Licensing Agreements - Additional Information - Celgene (Detail)	Dec. 23, 2014USD ($)Programs	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2019USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 29,544,000	$ 53,019,000	$ 51,762,000
Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		0
Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		0
Celgene [Member] | License Agreement [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of potential products to developed and commercialized | Programs	10
Collaborative agreement expansion fee	$ 4,000,000
Celgene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment	1,640,000,000
Celgene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Eligible to Receive [Member] | License Option [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	7,500,000
Celgene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Eligible to Receive [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	164,000,000
Celgene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Eligible to Receive [Member] | Maximum [Member] | Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	101,500,000
Celgene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Eligible to Receive [Member] | Maximum [Member] | Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 55,000,000
Celgene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue					$ 8,000,000
Celgene [Member] | Cross License Agreement [Member] | Collaborative Arrangement [Member] | Option Exercise Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 7,500,000

Research, Collaboration and L_8

Research, Collaboration and Licensing Agreements - Additional Information - GSK (Detail) - USD ($)	Dec. 01, 2015	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 29,544,000	$ 53,019,000	$ 51,762,000
Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		0
Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		0
Royalty [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		0
Glaxo Smith Kline Intellectual Property Development Ltd [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		0
Glaxo Smith Kline Intellectual Property Development Ltd [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		0
Glaxo Smith Kline Intellectual Property Development Ltd [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Royalty [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 0
Glaxo Smith Kline Intellectual Property Development Ltd [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Eligible to Receive [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 1,100,000,000
Glaxo Smith Kline Intellectual Property Development Ltd [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Eligible to Receive [Member] | Maximum [Member] | Research Development and Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 110,000,000

Research, Collaboration and L_9

Research, Collaboration and Licensing Agreements - Additional Information - GSK Two (Detail) - USD ($)	Dec. 31, 2019	Apr. 21, 2016	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2019
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			$ 29,544,000	$ 53,019,000	$ 51,762,000
Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			$ 0
Glaxo Smith Kline Intellectual Property Development Ltd [Member] | Eligible to Receive [Member] | Maximum [Member] | Milestone and Other Payments [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 1,100,000,000
Glaxo Smith Kline Intellectual Property Development Ltd [Member] | Platform Technology Transfer and License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue						$ 6,000,000
Glaxo Smith Kline Intellectual Property Development Ltd [Member] | Platform Technology Transfer and License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Eligible to Receive [Member] | Maximum [Member] | Research Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 37,500,000
Glaxo Smith Kline Intellectual Property Development Ltd [Member] | Platform Technology Transfer and License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Eligible to Receive [Member] | Maximum [Member] | Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	183,500,000
Glaxo Smith Kline Intellectual Property Development Ltd [Member] | Platform Technology Transfer and License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Eligible to Receive [Member] | Maximum [Member] | Commercial Sales Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 867,000,000

Research, Collaboration and _10

Research, Collaboration and Licensing Agreements - Additional Information - Daiichi Sankyo (Detail) - USD ($)	Dec. 31, 2019	Sep. 26, 2016	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2019
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			$ 29,544,000	$ 53,019,000	$ 51,762,000
Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			0
Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			$ 0
Cross License Agreement [Member] | Collaborative Arrangement [Member] | Eligible to Receive [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty percentage earned from sales of product		10.00%
Daiichi Sankyo, Co., Ltd [Member] | Cross License Agreement [Member] | Collaborative Arrangement [Member] | Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue						$ 2,000,000
Daiichi Sankyo, Co., Ltd [Member] | Cross License Agreement [Member] | Collaborative Arrangement [Member] | Research, Development, Commercial License Option Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue						$ 4,500,000
Daiichi Sankyo, Co., Ltd [Member] | Cross License Agreement [Member] | Collaborative Arrangement [Member] | Commercial Milestones [Member] | Eligible to Receive [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 80,000,000
Daiichi Sankyo, Co., Ltd [Member] | Cross License Agreement [Member] | Collaborative Arrangement [Member] | Development Milestone [Member] | Eligible to Receive [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment	$ 63,400,000
Daiichi Sankyo, Co., Ltd [Member] | Cross License Agreement [Member] | Collaborative Arrangement [Member] | Milestone and Other Payments [Member] | Eligible to Receive [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payment		$ 149,900,000

Research, Collaboration and _11

Research, Collaboration and Licensing Agreements - Additional Information - Daiichi Sankyo Two (Detail) - USD ($)	May 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 29,544,000	$ 53,019,000	$ 51,762,000
Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		0
Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		0
Royalty [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		0
Daiichi Sankyo, Co., Ltd [Member] | Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			$ 18,000,000
Daiichi Sankyo, Co., Ltd [Member] | License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		0
Daiichi Sankyo, Co., Ltd [Member] | License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		0
Daiichi Sankyo, Co., Ltd [Member] | License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Royalty [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 0
Daiichi Sankyo, Co., Ltd [Member] | License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Eligible to Receive [Member] | Royalty [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty agreement term	10 years
Daiichi Sankyo, Co., Ltd [Member] | License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Eligible to Receive [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 484,700,000
Daiichi Sankyo, Co., Ltd [Member] | License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Eligible to Receive [Member] | Maximum [Member] | Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	126,700,000
Daiichi Sankyo, Co., Ltd [Member] | License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Eligible to Receive [Member] | Maximum [Member] | Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 340,000,000
Daiichi Sankyo, Co., Ltd [Member] | License Agreement [Member] | Non-collaborative Arrangement Transactions [Member] | Eligible to Receive [Member] | Maximum [Member] | Royalty [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty percentage earned from sales of product	10.00%

Research, Collaboration and _12

Research, Collaboration and Licensing Agreements - Additional Information - Janssen (Detail) - USD ($)	Nov. 13, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 29,544,000	$ 53,019,000	$ 51,762,000
Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		0
Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		0
Royalty [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 0
Janssen Biotech, Inc. [Member] | Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue				50,000,000
Janssen Biotech, Inc. [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue				$ 50,000,000
Janssen Biotech, Inc. [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Development Milestone [Member] | Eligible to Receive [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 282,000,000
Janssen Biotech, Inc. [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Commercial Milestones [Member] | Eligible to Receive [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 1,120,000,000
Janssen Biotech, Inc. [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Royalty [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty agreement term	10 years
Payment for royalty	$ 10,000,000
Janssen Biotech, Inc. [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | License and Milestone Payments [Member] | Eligible to Receive [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 1,450,000,000

Research, Collaboration and _13

Research, Collaboration and Licensing Agreements - Additional Information - LEO (Detail) - USD ($)	Oct. 23, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 29,544,000	$ 53,019,000	$ 51,762,000
Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		0
Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 0
LEO Pharma [Member] | Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			5,000,000
LEO Pharma [Member] | Research and License Agreement [Member] | Collaborative Arrangement [Member] | Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 0
LEO Pharma [Member] | Research and License Agreement [Member] | Collaborative Arrangement [Member] | Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	0
LEO Pharma [Member] | Research and License Agreement [Member] | Collaborative Arrangement [Member] | Investigational New Drug [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 0
LEO Pharma [Member] | Research and License Agreement [Member] | Collaborative Arrangement [Member] | First Therapeutic [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty payments on future global net sales	20.00%
LEO Pharma [Member] | Research and License Agreement [Member] | Collaborative Arrangement [Member] | First Therapeutic [Member] | Maximum [Member] | Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 74,000,000
LEO Pharma [Member] | Research and License Agreement [Member] | Collaborative Arrangement [Member] | First Therapeutic [Member] | Maximum [Member] | Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	157,000,000
LEO Pharma [Member] | Research and License Agreement [Member] | Collaborative Arrangement [Member] | Second Therapeutic [Member] | Maximum [Member] | Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	86,500,000
LEO Pharma [Member] | Research and License Agreement [Member] | Collaborative Arrangement [Member] | Second Therapeutic [Member] | Maximum [Member] | Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 157,000,000
LEO Pharma [Member] | Research and License Agreement [Member] | Collaborative Arrangement [Member] | Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue			$ 5,000,000

Research, Collaboration and _14

Research, Collaboration and Licensing Agreements - Additional Information - BeiGene (Detail)	Nov. 26, 2018USD ($)Agreement	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		$ 29,544,000	$ 53,019,000	$ 51,762,000
Contract liabilities		32,941	36,471
Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		0
Development Milestone [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		0
Royalty [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		0
License Agreement [Member] | Collaborative Arrangement [Member] | Up-front Technology Access Fee [Member] | ZW49 Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities		32,941,000	36,471,000
Bei Gene [Member] | Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue		3,530,000	23,530,000
Bei Gene [Member] | Research and License Agreement [Member] | Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Performance obligation recognized			20,000,000
Bei Gene [Member] | Research and License Agreement [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Fair value of consideration allocated to a group of contracts that were considered as a single contract			40,000,000
Bei Gene [Member] | Research and License Agreement [Member] | Collaborative Arrangement [Member] | Bispecific Therapeutic [Member] | Maximum [Member] | Commercial and Development Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 702,000,000
Bei Gene [Member] | Research and License Agreement [Member] | Collaborative Arrangement [Member] | Up-front Technology Access Fee [Member] | Bispecific Therapeutic [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities			20,000,000
Bei Gene [Member] | License Agreement [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of agreements | Agreement	3
Bei Gene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | ZW25 Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Fair value of consideration allocated to a group of contracts that were considered as a single contract	$ 7,100,000
Bei Gene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | ZW25 and ZW49 Agreements [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty payments on future global net sales	20.00%
Bei Gene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | ZW25 and ZW49 Agreements [Member] | Maximum [Member] | Commercial Milestones [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 390,000,000
Bei Gene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Up-front Technology Access Fee [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payment received			60,000,000
Bei Gene [Member] | License Agreement [Member] | Collaborative Arrangement [Member] | Up-front Technology Access Fee [Member] | ZW25 Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contract liabilities		$ 32,941,000	$ 36,471,000

Research, Collaboration and _15

Research, Collaboration and Licensing Agreements - Additional Information - Iconic (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 29,544	$ 53,019	$ 51,762
Iconic Therapeutics Inc [Member] | Milestone Payment [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 1,000

Other expense, net -Schedule Of

Other expense, net -Schedule Of Other Non operating Income Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Other Income and Expenses [Abstract]
Foreign exchange (loss) gain	$ (567)	$ 72	$ 97
Change in fair value of warrant liabilities (note 10)		(3,565)	2,450
Loss on debt extinguishment (note 10)			(3,114)
Accretion expense			(248)
Other	(173)	(166)	(422)
Total	$ (740)	$ (3,659)	$ (1,237)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Line Items]
Expected income tax rate	27.00%	27.00%	26.00%
Net operating loss carry forwards	$ 122,300	$ 24,700
Tax credit carryforward, amount	8,075	9,000
Research [Member]
Income Tax Disclosure [Line Items]
Tax credit carryforward, amount	$ 58,200	$ 50,300
Earliest Tax Year [Member]
Income Tax Disclosure [Line Items]
Operating loss carry forwards, expiration year	2035
Tax credit carryforward, expiration year	2029
Earliest Tax Year [Member] | CANADA
Income Tax Disclosure [Line Items]
Income tax examination, year under examination	2006
Earliest Tax Year [Member] | UNITED STATES
Income Tax Disclosure [Line Items]
Income tax examination, year under examination	2016
Latest Tax Year [Member]
Income Tax Disclosure [Line Items]
Operating loss carry forwards, expiration year	2039
Tax credit carryforward, expiration year	2039
Latest Tax Year [Member] | CANADA
Income Tax Disclosure [Line Items]
Income tax examination, year under examination	2019
Latest Tax Year [Member] | UNITED STATES
Income Tax Disclosure [Line Items]
Income tax examination, year under examination	2019

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Tax Expense (Recovery) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Computed taxes at Canadian tax rate (27%)	$ 39,453	$ 9,284	$ 2,587
Non-deductible expenses	(13,020)	(4,311)	(259)
Difference between domestic and foreign tax rate	104	14	11
Effect of change in tax rates	(10)	(2)	860
Adjustments to prior year	(39)	(543)	313
Change in valuation allowance	(29,057)	(9,340)	(8,510)
Share issuance costs in equity	3,578	1,906	2,547
Change in recognition and measurement of tax positions	(2,391)	(672)
Changes due to SR&ED	2,200	1,668	1,973
Other	(236)	(175)	34
Income tax expense (recovery)	582	(2,171)	(444)
Current income tax expense	(1,373)	(2,188)	(429)
Deferred income tax recovery (expense)	1,955	17	(15)
Income tax recovery (expense)	$ 582	$ (2,171)	$ (444)

Income Taxes - Summary of Signi

Income Taxes - Summary of Significant Components of Deferred Income Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Deferred tax assets:
Non-capital losses carried forward	$ 33,016	$ 6,680
Deferred revenue	8,894	9,848
Share issue costs	5,473	3,428
Property and equipment	1,731	1,167
Research and development deductions and credits	21,813	20,749
Contingent consideration	264	191
Stock options	1,242	220
Operating lease liability	1,540
Other	348	314
Deferred Tax Assets, Gross	74,321	42,597
Deferred tax liabilities:
Property and equipment	(583)	(54)
IPR&D	(4,760)	(4,967)
Operating lease right-of-use assets	(1,016)
Other	(408)	(132)
Deferred tax liabilities, Gross	(6,767)	(5,153)
Deferred Tax Assets (Liabilitites) Before Valuation Allowance	67,554	37,444
Deferred Tax Assets, Valuation Allowance	(66,744)	(37,360)
Net deferred tax assets (liabilities)	810	84
Deferred tax asset	1,218	198
Deferred tax liabilities	(408)	(114)
Net deferred tax assets (liability)	810	84
Deferred Tax Net [Member]
Deferred tax liabilities:
Net deferred tax assets (liabilities)	810	84
Net deferred tax assets (liability)	$ 810	$ 84

Income Taxes - Summary of Expir

Income Taxes - Summary of Expiry Details of Investment Tax Credits, Non-Capital Losses and Net Operating Losses for Income Tax Purposes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Investment tax credits	$ 8,075	$ 9,000
Non-capital losses	$ 122,281
Tax Year 2029 [Member]
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Expiry Date	2029
Investment tax credits	$ 1,078
Tax Year 2030 [Member]
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Expiry Date	2030
Tax Year 2031 [Member]
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Expiry Date	2031
Tax Year 2032 [Member]
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Expiry Date	2032
Tax Year 2033 [Member]
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Expiry Date	2033
Tax Year 2034 [Member]
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Expiry Date	2034
Investment tax credits	$ 230
Tax Year 2035 [Member]
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Expiry Date	2035
Investment tax credits	$ 1,068
Non-capital losses	$ 3,961
Tax Year 2036 [Member]
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Expiry Date	2036
Investment tax credits	$ 878
Non-capital losses	$ 24,578
Tax Year 2037 [Member]
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Expiry Date	2037
Investment tax credits	$ 1,587
Non-capital losses	$ 10,625
Tax Year 2038 [Member]
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Expiry Date	2038
Investment tax credits	$ 1,485
Tax Year 2039 [Member]
Summary Of Tax Credit Carry Forward And Operating Loss Carry Forwards [Line Items]
Expiry Date	2039
Investment tax credits	$ 1,749
Non-capital losses	$ 83,117

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Beginning and Ending Amounts of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Balance, beginning of year	$ 672
Increases related to prior year tax positions	0	142
Increases related to current year tax positions	2,391	530
Balance, end of year	$ 3,063	$ 672

Leases - Additional Information

Leases - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Lease description	The Company entered into a lease on January 25, 2019 in Vancouver to serve as the Company’s future head office, including both office and laboratory space. The commencement date of this lease depends upon completion of construction of the building and is currently estimated to be no later than September 1, 2021. This lease has an initial term of ten years, with two five-year extension options.
Weighted Average Remaining Lease Term	4 years 3 months 18 days
Operating lease expense	$ 2,845
Fixed lease payment	2,639
Variable lease payment	$ 251
BRITISH COLUMBIA
Lease Expiration Date	Aug. 1, 2021
Canada, Dollars
Discount Rate	4.60%
United States of America, Dollars
Discount Rate	2.90%

Leases - Schedule of Balance Sh

Leases - Schedule of Balance Sheet Classification of Lease Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Leases [Abstract]
Current portion	$ 1,282
Long-term portion	5,599
Operating lease liabilities	6,881	$ 3,561
Current portion included in other current liabilities	10		$ 15
Long-term portion included in other long-term liabilities	46		42
Total finance lease liabilities	56		57
Total lease liabilities	$ 6,937		$ 57

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Lease Payment Operating Lease Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Jan. 01, 2019
Leases [Abstract]
Within 1 year	$ 1,438
1 to 2 years	2,076
2 to 3 years	1,007
3 to 4 years	991
4 to 5 years	1,019
Thereafter	781
Total operating lease payments	7,312
Imputed interest	(431)
Operating lease liabilities	$ 6,881	$ 3,561

Leases - Schedule of Maturities

Leases - Schedule of Maturities of Finance Lease Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Leases [Abstract]
Within 1 year	$ 31
1 to 2 years	16
2 to 3 years	6
3 to 4 years	3
4 to 5 years	1
Thereafter	0
Total finance lease payments	57
Imputed interest	(1)
Finance lease liabilities	$ 56	$ 57

Financial Instruments - Schedul

Financial Instruments - Schedule of Financial Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Liabilities
Financial liabilities measured at fair value	$ 46,547	$ 13,310
Liability Classified Stock Options [Member]
Liabilities
Financial liabilities measured at fair value	45,569	12,603
Liability for Contingent Consideration [Member]
Liabilities
Financial liabilities measured at fair value	978	707
Level 3 [Member]
Liabilities
Financial liabilities measured at fair value	46,547	13,310
Level 3 [Member] | Liability Classified Stock Options [Member]
Liabilities
Financial liabilities measured at fair value	45,569	12,603
Level 3 [Member] | Liability for Contingent Consideration [Member]
Liabilities
Financial liabilities measured at fair value	$ 978	$ 707

Financial Instruments - Summary

Financial Instruments - Summary of Changes in Fair Value of the Company's Liability for Contingent Consideration (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Liability at the beginning of the period	$ 707	$ 470
Increase (decrease) in fair value of liability for contingent consideration	271	237	$ 470
Liability at end of the period	$ 978	$ 707	$ 470

Financial Instruments - Sched_2

Financial Instruments - Schedule of Changes in Fair Value of Warrant Liabilities (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Liability at the beginning of the period	$ 0	$ 1,348
Reclassification to liability from equity	0	0
Increase (decrease) in fair value of warrant liabilities		3,565
Exercise of warrants		(4,913)
Liability at end of the period	$ 0	$ 0

Financial Instruments - Sched_3

Financial Instruments - Schedule of Changes in Fair Value of Liability Classified Stock Options (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liability at beginning of the period	$ 12,603
Reclassification to liabilities from equity	0	$ 0
Liability at end of the period	45,569	12,603
Liability Classified Stock Options [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liability at beginning of the period	12,603	3,945
Reclassification to liabilities from equity	119	0
Increase (decrease) in fair value of liability classified stock options	35,994	9,451
Exercise of options	(3,804)	(142)
Unrealized foreign currency loss (gain)	657	(651)
Liability at end of the period	$ 45,569	$ 12,603

Financial Instruments - Additio

Financial Instruments - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Financial Instruments [Line Items]
Maximum exposure to credit risk for accounts receivable	$ 2.2	$ 0.4
Capital lease due, period	12 months
Accounts Payable and Accrued Liabilities [Member]
Financial Instruments [Line Items]
Financial obligation due, period	45 days

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Aug. 31, 2016
Contractual Obligation, Fiscal Year Maturity Schedule [Abstract]
Aggregate payment for annual licensing fees	$ 0	$ 12,000
Annual licensing fees payment period	five-year period

Subsequent event - Additional I

Subsequent event - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	Jan. 27, 2020	Jun. 24, 2019	Jun. 11, 2018	Apr. 28, 2017
Subsequent Event [Line Items]
Final prospectus supplement, shares price				$ 13
Offering [Member]
Subsequent Event [Line Items]
Final prospectus supplement, shares price		$ 18	$ 15.75
Warrants issued price per pre funded warrant		$ 17.9999
Number of shares issued		7,013,892	6,210,000
Net proceeds from issuance | $		$ 188	$ 90.8
Subsequent Event [Member] | Offering [Member]
Subsequent Event [Line Items]
Final prospectus supplement, shares price	$ 46.50
Warrants issued price per pre funded warrant	$ 46.4999
Number of shares issued	4,924,729
Number of shares issued to underwriters	900,000
Pre funded warrants issued in lieu of common shares to underwriters	1,075,271
Net proceeds from issuance | $	$ 301